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 The Rift Valley fever virus (RVFV) is responsible for numerous, explosive 
epizootics throughout Africa and the Arabian Peninsula. The virus causes disease 
predominantly in humans and livestock, with sheep and cattle being particularly 
susceptible.  In humans, the disease generally manifests as a flu-like illness; however, in 
a small percentage of cases, severe symptoms develop, such as encephalitis and 
hemorrhagic fever disease.  In these severe cases, mortality rates are high.   Livestock 
often succumb to the viral infection, and case-fatality rates are particularly high among 
young animals.  Outbreaks are devastating to the public health and regional economies, 
and the development of antiviral therapies is difficult due to the limited understanding of 
the RVFV replicative cycle.   
We have developed a system for the generation of Rift Valley fever virus-like 
particles (RVF-VLPs).  The RVF-VLPs are antigenically and morphologically 
indistinguishable from virulent RVFV virus, but can only perform a single round of 
infection.  Using the virus-like particle system for RVFV, in combination with 
biochemical and crystallization techniques, we have elucidated the roles of the viral 
proteins in multiple steps of the viral replicative cycle.  Specifically, we describe crucial 
interactions necessary for replication and transcription, elucidate the structure of the 
nucleocapsid protein, identify the envelope glycoprotein, Gn, as necessary and sufficient 
viii 
for the recruitment and packaging of the RdRp and encapsidated genome into virus 
particles, determine that the encapsidated genome triggers the efficient release of virus, 
and ascertain the limitations governing RVFV reassortment with other phleboviruses.  
Based on our results, we suggest targets for the development of therapeutics directed 



















Chapter 1  
 
Introduction 
Negative-sense RNA viruses 
RNA viruses are ubiquitous in nature and have developed parasitic relationships 
with most organisms, from bacteria to plants to humans.  The co-evolution of RNA 
viruses with their hosts requires the viruses to constantly evolve in response to changes in 
host defense or to better thrive in a particular environment.  The negative-sense, 
segmented RNA viruses are particularly adept at rapidly responding to selective 
pressures, utilizing processes of antigenic drift and antigenic shift.   
Negative-sense RNA viruses encompass an array of human pathogens, including 
influenza A, Ebola, rabies, Andes, and Rift Valley fever viruses.   These viruses may 
contain either an unsegmented or segmented RNA genome.  The unsegmented RNA 
viruses belong to the order Mononegavirales, and include the rabies (Rhabdoviridae), 
measles (Paramyxoviridae), Ebola (Filoviridae), and borna disease (Bornaviridae) 
viruses (Fig. 1.1).  Virus families outside the Mononegavirales order have varying 
numbers of genomic segments, and include the influenza A (Orthomyxoviridae), Rift 
Valley fever (Bunyaviridae), and Andes (Arenaviridae) viruses, which have eight, three, 
and two genomic segments, respectively (Fig. 1.1).  The viruses of the Bunyaviridae and 
Arenaviridae families contain genomic segments of negative-sense and ambisense 
polarity (Fig. 1.2).  In contrast to positive-sense RNA viruses, which contain genomes 
that are essentially mRNA and can be translated upon infection of host cells, negative-
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sense RNA virus genomes must be transcribed by a viral polymerase prior to translation 
(Fig. 1.2).  The ambisense genomic segments encode viral genes encoded in the negative-
sense RNA, as well as in the RNA complementary (cRNA) to the negative-sense genome 
(Fig. 1.2).  The cRNA is generated as an intermediate during replication. 
The segmented, negative-sense RNA viruses have a unique capability for rapidly 
responding to selective pressures through a process known as antigenic shift, or 
reassortment.  When two related viruses co-infect the same cell, progeny can be produced 
that have packaged genomic segments from both parental viruses, forming a novel virus.  
The progeny virus may be more pathogenic or have a greater fitness in a particular 
environment (Fig. 1.3).  Segmented RNA viruses can rapidly evolve to new environments 
or hosts through reassortment, and the reassortment of viruses belonging to the 
Orthomyxoviridae and Bunyaviridae families has been previously documented.  The 
virus strain responsible for the global outbreak of the influenza A virus 
(Orthomyxoviridae) H1N1 in 2009 originated from multiple reassortment events between 
human, avian, and swine influenza A virus strains (1, 2).  As a result of the reassortment 
events, the influenza A virus could replicate in a range of hosts.   
Reassortment of viruses within the Bunyaviridae family has been observed among 
different strains of the same virus (3-9), as well as between different viruses within the 
same genus (5, 10-18).  In the Orthobunyavirus genus (Bunyaviridae family), Ngari virus 
is known to cause hemorrhagic fever disease and was isolated from regions throughout 
Kenya and Somalia (10, 19).  Upon sequencing of the viral genome, it was found to 
contain two segments from the Bunyamwera virus, and one segment from the Batai virus 
(11, 17, 19).  The Bunyamwera virus typically causes a febrile disease, while the Batai 
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virus had not been previously documented as causing human disease (11).  The reassorted 
progeny virus was found to cause hemorrhagic fever disease in humans, exhibiting a 
similar, yet more severe pathogenesis compared to the documented cases of the 
Bunyamwera virus (10).  
Natural and experimental evidence suggests that different viruses in the genera 
Orthobunyavirus and Hantavirus of the Bunyaviridae family can reassort (5, 10-16, 18).  
Within the Bunyaviridae family, there is little information on the interactions between the 
viral proteins necessary for replication/transcription, assembly, and cellular release.  A 
better understanding of the viral replicative cycle for bunyaviruses would aid in 
predicting which bunyaviruses may be capable of reassorting.  The public health threat 
posed by the reassortment of highly pathogenic viruses in the Bunyaviridae family is 
significant, and could extend the geographical range, host or vector species susceptibility, 
and/or pathogenesis of the viruses.  Discovery of the viral interactions restricting 
bunyavirus reassortment is critical for the public health preparation of future global 
epidemics.  
Rift Valley fever virus 
The Rift Valley fever virus (RVFV) is one of the more pathogenic viruses within 
the Bunyaviridae family (Phlebovirus genus) (20), capable of causing enormous 
epizootics throughout Africa, with human symptoms ranging from fever and malaise to 
encephalitis and hemorrhagic fever.  The severe pathogenesis associated with RVFV, the 
wide range of mosquito vectors capable of transmitting the virus (21-28), the ability of 
viruses of other genera of the Bunyaviridae family to reassort, and the presence of other 
highly-related viruses in nearby regions increase the importance of understanding the 
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mechanisms of RVFV replication and transcription, assembly, and cellular release for the 
identification of RVFV therapeutic targets, as well as for determining the potential for 
viral reassortment.  There are no FDA-approved therapeutics or prophylactics available, 
and little is known about the replication cycle of RVFV.   
Epidemiology 
RVFV is an aerosol- and mosquito-borne virus endemic to sub-Saharan Africa. 
RVFV causes disease in both livestock and humans, with sheep and cattle being 
particularly susceptible (29).  In livestock, the virus can cause high rates of mortality, 
especially among young animals, and near 100% abortion rates (30).  In humans, the 
disease generally manifests as a flu-like illness with fever and fatigue, but in a small 
number of cases the disease progresses to more severe manifestations, such as retinitis, 
hepatitis, encephalitis, and hemorrhagic fever disease (29, 31, 32).  Mortality rates are 
nearly 50% among hemorrhagic fever cases (31).  Due to the explosive nature of the 
RVFV epizootics, the high number of infected individuals can result in hundreds of 
fatalities.  In the 1978-79 RVFV outbreak in Egypt, between 20,000 - 200,000 people 
were predicted to have been infected, generating more than 600 fatalities (30).  
Emergence and dissemination of RVFV throughout Africa and Arabian Penninsula 
RVFV was first isolated in 1930 from the Great Rift Valley in Kenya from 
infected lambs.  Since its identification, serological sampling has demonstrated the 
presence of RVFV throughout most of Africa, including Madagascar (4).  Phylogenetic 
analysis of the various RVFV strains throughout Africa suggests that the progenitor strain 
of RVFV arrived in the late 1800s, around the same time as African colonization and the 
arrival of European domesticated animals (4). European animals appear more susceptible 
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to RVFV infection than the African species of livestock, and their arrival may have 
increased the magnitude of the epizootics (4).  Phylogenetic analyses also suggest that 
individual RVFV strains have traveled great distances, likely through the transport of the 
mosquito vector or infected host species (4).   
In 1977, the first outbreak of RVFV in Egypt resulted in extensive human and 
animal infection, and it is believed to have been caused by the border-crossing of infected 
animals from Kenya (33).  The emergence of RVFV epizootics in West Africa and the 
Arabian Peninsula was also associated with human activities.  In 1987, the first RVFV 
outbreak in West Africa was associated with dam construction, which produced favorable 
breeding grounds for mosquitos (34).  In 2000, RVFV spread outside the African 
continent to the Arabian Peninsula, apparently due to trade of infected cattle from eastern 
Africa (4).  The restriction of the virus to the African continent appears to be mainly due 
to its geographical/physical isolation from the rest of the world.   
Transmission 
The mosquito is the vector for RVFV, and epizootics occur during times of heavy 
rainfall.  Normally dry inland depressions known as damboes flood during periods of 
intense rainfall creating favorable conditions for mosquito breeding.  The Aedes 
subspecies of mosquito is the primary vector for the virus, and it can transmit the virus 
transovarially to its eggs (35).  The virus has been found to persist in the periods between 
epizootics in infected mosquito eggs, possibly representing the viral reservoir (35).  
During periods of heavy rainfall, the infected young hatch and feed on nearby animals, 
including domesticated sheep and cattle.  Amplification of the virus occurs with the 
hatching of the Culex and other subspecies of mosquito, which feed on the RVFV-
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infected animals (30).  The Culex mosquitos can further aid in transmission of the virus 
by continued feeding.  Human infections occur either through direct transmission from 
mosquito or through contact with infected tissues or aerosol during the maintenance or 
slaughter of infected animals (6).  Due to its ability to be transmitted through aerosol, 
RVFV could also be used as an agent for biological warfare or bioterrorism.  For 
example, the US biological warfare program weaponized RVFV prior to termination of 
the effort in 1969 (36).   
Upon transmission, the virus is proposed to travel to the lymphatic system, then 
enter the bloodstream for dissemination throughout the body (35).   In infected animals, 
the virus affects most internal organs, including liver, spleen, and brain (35, 37, 38), and 
death is often associated with necrosis of the liver (39).  Some studies suggest the liver is 
the primary target for RVFV; however, the high volume of blood that circulates through 
the liver may simply deliver more virus to this organ.  
The vectors for RVFV transmission are found throughout the world, and the 
introduction of RVFV into previously unaffected areas has resulted in large epizootics.  
World trade, global warming, and human activities, such as deforestation and the 
construction of dams and roads, increase the likelihood that RVFV will spread from 
Africa and the Arabian Peninsula in the future.  RVFV is devastating to the public health 
and the economy in affected areas, and the capacity to spread to unaffected regions of the 
world highlights the necessity in understanding the replicative cycle of the virus. Through 
gaining a better understanding of the viral replication, new prophylactic and therapeutic 
targets can be identified.   
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Replicative cycle 
The replicative cycle of RVFV initiates with the entry of the virus into host cells. 
Similar to all bunyaviruses, RVFV is spherical, enveloped, and contains three negative-
sense (or ambisense) RNA genomic segments, termed the large (L), medium (M), and 
small (S) segments (Fig. 1.4) (40).  Upon cellular entry, RVFV releases the encapsidated 
genome into the cytoplasm, where replication and transcription occurs. The 3’ and 5’ 
termini contain the untranslated regions (UTRs) of the viral genomic segments, and the 
terminal complementary nucleic acids are proposed to base-pair and generate a panhandle 
structure (Fig. 1.4) (41). The transcriptional promoters and terminators for the RNA-
dependent RNA polymerase (RdRp) reside within the UTRs, with the exception of the S 
segment, which is ambisense and terminates transcription in the intergenic region (42).  
The S, M, and L segments encode the nucleocapsid protein (N), envelope 
glycoproteins (Gn/Gc), and the RdRp, respectively (Fig. 1.4) (40).  The M and S 
segments also encode nonstructural proteins, NSm and NSs (40).  NSm appears to exhibit 
anti-apoptotic activity (43), while NSs inhibits the host immune response through 
interactions with TFIIH and SAP30 and downregulation of PKR expression (44-46).   
NSs and NSm are not required for viral replication in cell culture (47, 48).  After 
transcription of the viral genes, Gn/Gc is translated as a polyprotein on the endoplasmic 
reticulum (ER), while the RdRp and N, which do not contain signal peptides, are 
presumably translated on free ribosomes in the cytoplasm (40).  Gn/Gc is cleaved by 
signal peptidase in the ER into the Gn and Gc glycoproteins, which are glycosylated as 
they mature through the secretory system (49). Gn localizes to the Golgi apparatus 
independently, and complex formation between Gn and Gc results in the masking of the 
Gc ER retention signal and co-translocation of Gc to the Golgi apparatus (50).  RdRp and 
8 
N localize to the cytoplasm, and must be recruited to the Golgi apparatus for assembly.  
Since bunyaviruses do not encode a matrix protein, it is hypothesized that the 
cytoplasmic tails of the envelope glycoproteins are involved in their recruitment.  
Following assembly, the virus buds into the lumen of the Golgi apparatus, and virus is 
released from the cell when virus-containing Golgi-derived vesicles fuse with the plasma 
membrane (40).  The stimulus for virus budding into the Golgi is unknown, as are the 
viral components necessary for virus release.  
Through our investigations with RVFV, we have elucidated various steps in the 
RVFV replicative cycle.  We describe critical interactions necessary for replication and 
transcription, detail the viral protein-protein interactions involved in the recruitment and 
packaging of the RdRp and encapsidated genome into virus particles, determine the viral 
components necessary for efficient release of virus, and ascertain the limitations 
governing RVFV reassortment with other phleboviruses.  Based on our results, we 






Figure 1.1.  Classification of negative-sense RNA viruses. 
Negative-sense RNA viruses are comprised of viruses with segmented or unsegmented genomes.  Virus 
families of the Mononegavirales order have unsegmented genomes, while virus families outside of this 





Figure 1.2.  Replication and transcription strategies of single-strand RNA viruses.   
In contrast to positive-sense RNA genomes, which are essentially mRNA and can be translated directly 
upon infection of host cells, negative-sense RNA virus genomes must be transcribed by the viral RdRp into 
mRNA prior to translation.  Viruses of the negative-sense RNA virus families, Bunyaviridae and 
Arenaviridae, also contain ambisense RNA genomic segments, which encode viral genes in both the viral 
sense and complementary sense RNA.  Therefore, one gene can be transcribed directly from the viral RNA, 
while the other gene cannot be transcribed until the complementary RNA is generated as an intermediate 
during viral replication of the genome.  The black rectangles represent the untranslated regions (UTRs) of 
the genomic segments.  RNA viruses are diverse, and although the genomes in this figure are depicted as 





Figure 1.3.  Reassortment of segmented negative-sense RNA viruses. 
Co-infection of a cell with two segmented RNA viruses can result in the production of particles that contain 
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Figure 1.4.  Schematic of RVFV genome. 
(A) The RVFV genome is divided into the large (L), medium (M), and small (S) segments.  The L and M 
segments are negative-sense and encode the RdRp and envelope glycoproteins, respectively.  The S 
segment is ambisense, encoding the NSs and N.  (B) The 3’ and 5’ termini of the RVFV genomic segments 
are comprised of complementary nucleotides that are predicted to base-pair, forming a panhandle structure.  
The termini contain the promoters necessary for replication and transcription, as well as packaging of the 
genomic segments into viral particles.  The eight terminal residues are conserved within the Phlebovirus 
genus. 
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Chapter 2  
 




The Rift Valley fever virus (RVFV) is a vector- and aerosol-borne virus endemic 
to sub-Saharan Africa. RVFV can cause disease in humans and in common livestock 
species, such as sheep and cattle. Pregnant animals exhibit a high incidence of abortion 
and young animals frequently succumb to infection (40). People typically develop a flu-
like illness; however, more severe manifestations, such as hemorrhagic fever or 
encephalitis, occur in a small percentage of cases. The hemorrhagic and encephalitic 
forms of disease exhibit high case-fatality rates (29, 31, 32). Competent vectors of RVFV 
are found worldwide (21-24, 26-28, 51), and release of the virus into a new region would 
be damaging for both the economy and public health. In 2000, the first documented 
outbreak of the virus outside of the African continent occurred on the Arabian Peninsula, 
and the virus was determined to be of East African origin (52, 53). The presence of the 
virus outside of Africa demonstrates the ability of the virus to spread to previously 
unaffected regions of the world.  Thus, geographic isolation appears to be mainly 
responsible for the containment of the virus to African regions. No licensed vaccines or 
therapeutic treatments are available; our RVF-VLP system will aid in the screening of 
small molecule inhibitors for the development of novel therapeutics. 
RVFV is an enveloped virus belonging to the Phlebovirus genus of the 
Bunyaviridae family. RVFV contains a negative-sense RNA genome that is divided into 
three segments, termed the small (S), medium (M), and large (L) segments. The S 
segment encodes the nucleocapsid protein (N), which encapsidates the viral RNA 
genome, and a nonstructural protein, NSs, which is involved in inhibition of the host 
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innate-immune response (40). The M segment encodes the envelope glycoproteins, Gn 
and Gc, and a nonstructural protein, termed NSm, while the L segment encodes an RNA-
dependent RNA polymerase (RdRp). The nonstructural proteins, NSs and NSm, are not 
required for viral replication in cell culture (47, 48, 54). Transcription and replication of 
the viral genome is initiated through the recognition of promoter sequences in the 5’ and 
3’ terminal untranslated regions (UTRs) of each genomic segment (55, 56). These 
processes occur in the cytoplasm and require both RdRp and N (40, 57). The RdRp and N 
are translated in the cytoplasm, while the envelope glycoproteins enter the secretory 
system. Gn and Gc form a complex and localize in steady-state to the Golgi apparatus 
due to a signal found on Gn (49, 50, 58). The assembled virus buds into the lumen of the 
Golgi apparatus, and virions are released from the cell when elements of the Golgi fuse 
with the plasma membrane.  
We have developed a T7 RNA polymerase (T7 RNAP)-dependent system for the 
production of infectious RVFV-like particles (RVF-VLPs) that obviates the need for 
high-level biosafety containment and allows for generation of viral particles that are 
antigenically indistinguishable from authentic RVFV. RVF-VLPs can deliver a 
minigenome to target cells, and expression of RdRp and N in target cells is not necessary 
for generation of significant reporter activity. Minigenome activity is inhibited by the 
same chemical compounds that inhibit authentic RVFV replication. RVF-VLPs are 
efficiently produced in our system, which should facilitate future studies aimed at 
examination of virus assembly and screening for small molecule inhibitors of viral entry 
and replication. 
Results 
System for Production of RVF-VLPs from Cloned cDNAs 
 We utilized a set of plasmids similar to that described for rescue of the virulent 
ZH-501 strain of RVFV as the basis of our RVF-VLP system (Table 2.1) (54). To assess 
production of RVF-VLPs, a minigenome based on the S segment was generated such that 
the NSs open reading frame was replaced with a gene encoding a reporter molecule, such 
as GFP or renilla luciferase (RLuc) (Fig. 2.1). Additionally, the vector backbone of all 
transcription plasmids was changed to one with transcriptional silencers flanking the 
15 
cloning site (see Methods section). The new vector dramatically reduced the background 
expression of the reporter gene (data not shown). An additional transcription plasmid was 
constructed that lacked 237 nucleotides of the N gene in order to investigate the 
contribution of N and minigenome independently in the generation and infectivity of 
RVF-VLPs (Fig. 2.1). Immunofluorescence microscopy (Fig. 2.2) and immunoblot (data 
not shown) using a polyclonal antibody recognizing full-length N failed to detect N 
expression. These S segment-based plasmids will henceforth be referred to as 
minigenome plasmids.  
A schematic detailing our method for RVF-VLP production and analysis is shown 
in Fig. 2.3. The minigenome along with expression plasmids for N, RdRp, and Gn/Gc are 
transfected into BSR-T7/5 cells (Fig. 2.3). The BSR-T7/5 cells constitutively express T7 
RNAP, which drives production of the primary minigenome transcript. Expression of the 
reporter from the minigenome in transfected cells requires co-expression of RdRp and N. 
Co-expression of Gn/Gc results in the production of RVF-VLPs containing the 
minigenome (Fig. 2.3). The RVF-VLPs are released from the cells into the media and are 
then used to infect target cells (Fig. 2.3). Replication of the minigenome and expression 
of RLuc or GFP in RVF-VLP-infected target cells relies on packaging of the 
encapsidated minigenome and RdRp. The RVF-VLPs do not contain the L or M genomic 
segments. Additionally, the S segment-based minigenome lacks the NSs gene and, in 
some experiments, the N gene. Therefore, RdRp, Gn/Gc, and, in some cases, N cannot be 
synthesized in infected target cells, and thus further production of RVF-VLPs is 
prevented. 
Production of Infectious RVF-VLPs. 
We investigated the ability of the recombinant structural proteins, N, RdRp and 
Gn/Gc, to replicate and transcribe the minigenome in transfected BSR-T7/5 cells. 
Replication of the minigenome requires expression of N and RdRp, but not Gn/Gc (57). 
Cells transfected with minigenome and pN, but not pRdRp and pGn/Gc, were unable to 
transcribe the minigenome reporter (Fig. 2.4, EV/EV), and the RLuc activity in these 
samples was considered background. The addition of pRdRp resulted in RLuc activity at 
levels greater than 1,500-fold background levels (Fig. 2.4, RdRp/EV). Though Gn/Gc is 
not required for replication of the minigenome, Gn/Gc expression further increased the 
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production of RLuc in transfected cells to levels greater than 40,000-fold background 
(Fig. 2.4, RdRp/Gn/Gc). The increase in RLuc expression could be due to an effect of 
Gn/Gc on RdRp activity or due to RVF-VLP-infection of other cells in the monolayer.  
RVF-VLPs released into the media from the transfected cells (Fig. 2.4) were used 
to infect various target cells, and RLuc expression in the RVF-VLP-infected target cells 
was measured. Cells receiving media from cells transfected with minigenome, pN, and 
pRdRp (RdRp/EV) did not generate RLuc expression greater than background for any 
timepoint or cell type investigated (Fig. 2.5). By contrast, target cells receiving media 
from cells transfected with minigenome, pN, pRdRp, and pGn/Gc (RdRp,Gn/Gc) 
produced RLuc activity substantially above background for all timepoints and cell types 
(Fig. 2.5). Therefore, infectious RVF-VLP production is dependent on expression of 
Gn/Gc.  
The production of RVF-VLPs peaked at 48 h post-transfection; however, 
considerable amounts of RVF-VLPs were released at 72 h post-transfection (Fig. 2.5).  
RLuc activity in RVF-VLP-infected target cells did not require expression in trans of the 
T7 RNAP or RdRp and N. RVF-VLP-infection of Vero E6 cells, which do not express 
the T7 RNAP or any viral proteins, produced RLuc levels that were over 200-fold 
background (Fig. 2.5). However, the addition of support plasmids did increase RLuc 
activity in BSR-T7/5 and Vero E6 cells. For instance, at the 48 h timepoint, expression of 
RdRp and N in BSR-T7/5 cells increased RLuc activity greater than 15-fold, and 
expression of RdRp in Vero E6 cells increased RLuc activity 1.8-fold (Fig. 2.5).  
RVF-VLPs are Efficiently Produced 
Using the green fluorescent protein (GFP) version of the minigenome, we 
investigated whether the increase in RLuc activity in transfected cells due to expression 
of Gn/Gc (Fig. 2.4) was caused by RVF-VLP infection of cells in the transfected cell 
monolayer. BSR-T7/5 cells transfected with the GFP minigenome, pN, and either empty 
vector (EV/EV), pRdRp and empty vector (RdRp/EV) or pRdRp and pGn/Gc 
(RdRp/Gn/Gc) were visualized by fluorescence microscopy (Fig. 2.6A). As expected, no 
GFP signal was detected in cells that lacked RdRp and Gn/Gc (Fig. 2.6A, EV/EV). 
However, in cells that expressed RdRp (RdRp/EV) or RdRp and Gn/Gc (RdRp/Gn/Gc), 
GFP expression was evident (Fig. 2.6A). Although the signal intensity increased over 
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time in cells that lacked Gn/Gc, the percentage of cells expressing GFP did not increase 
(Fig. 2.6A). With addition of the glycoproteins (RdRp/Gn/Gc), the intensity of GFP 
fluorescence as well as the percentage of cells expressing GFP increased over time (Fig. 
2.6A). Therefore, it appears that the increase in RLuc activity observed in the experiment 
shown in Figure 2.4 is mainly due to spread of RVF-VLPs in the transfected cell 
monolayer. 
The media harvested from the transfected cells (Fig. 2.6A) at 24, 48, or 72 h post-
transfection was placed onto target cells, and GFP expression was visualized by 
fluorescence microscopy (Fig. 2.6B). Target cells receiving harvested media from cells 
lacking Gn/Gc did not produce any GFP, while target cells receiving media from cells 
expressing Gn/Gc did exhibit GFP expression. The number of cells expressing GFP and 
the intensity of GFP expression was greatest for cells infected with RVF-VLPs 
(RdRp/Gn/Gc) harvested 48 h post-transfection. However, RVF-VLP production 
appeared to exhibit high yields at 72 h post-transfection, mimicking the RLuc results 
shown in Figure 2.5. The majority of the cells in the monolayer appeared to express GFP 
after RVF-VLP (RdRp/Gn/Gc) infection, demonstrating that RVF-VLPs were efficiently 
produced.  
RVF-VLPs are Antigenically Indistinguishable from Authentic RVFV 
To determine whether RVF-VLPs and virulent RVFV are antigenically 
indistinguishable, RVF-VLPs were investigated for their ability to be neutralized by 
RVFV neutralizing antibodies.  BSR-T7/5 cells were transfected with minigenome, pN, 
pRdRp, and pGn/Gc. The media containing RVF-VLPs was harvested and clarified, and 
then incubated with antibodies recognizing RVFV or not incubated with antibody 
(Mock). The media was then transferred to BSR-T7/5 target cells, and RLuc activity was 
measured at 24 h post-infection. The level of RLuc activity in cells infected by RVF-
VLPs receiving the Mock treatment represents 100% infectivity (Fig. 2.7). Incubation of 
the RVF-VLPs with neutralizing polyclonal antibodies to RVFV nearly completely 
neutralized the RVF-VLPs and resulted in minigenome activity levels that were only 1% 
of the Mock treatment (Fig. 2.7). Incubation with neutralizing monoclonal antibodies 
recognizing the envelope glycoproteins (59), which are exposed on the surface of the 
RVF-VLPs, neutralized the RVF-VLPs dramatically, allowing only 6% activity (Fig. 
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2.7). By contrast, monoclonal antibodies recognizing N, which is not exposed on the 
surface of the RVF-VLPs, did not significantly reduce infectivity of the RVF-VLPs (Fig. 
2.7).  These antibodies were evaluated on the same strain of RVFV (ZH-501) that was 
used to generate our VLP system (data not shown), and the same trends were observed. 
Our results suggest that the RVF-VLPs are antigenically similar to virulent RVFV. 
RVF-VLPs are Efficiently Harvested by High-Speed Centrifugation 
To assay cellular release of particles and to determine the protein content of RVF-
VLPs, we devised a method for harvesting the RVF-VLPs in order to assay cellular 
release of particles and to determine the protein content of RVF-VLPs. BSR-T7/5 cells 
were transfected with minigenome, pN, pRdRp, and either pGn/Gc or empty vector. At 
48 h post-transfection, the media from transfected cells was harvested, clarified, and 
RVF-VLPs were pelleted by ultracentrifugation. The concentrated RVF-VLPs in the 
pellet were either resuspended in the supernatant (Fig. 2.8; Pellet + Supernatant) or the 
supernatant was decanted (Figure 2.8; Supernatant), and the pellet was resuspended in 
equivalent amount of fresh media (Fig. 2.8; Pellet). These samples were used to infect 
BSR-T7/5 cells that expressed RdRp and N. At 24 h post-infection, the cells were 
harvested, and RLuc activity was measured. RLuc activity in BSR-T7/5 cells that were 
infected with the passage containing both the supernatant and pellet fractions represents 
100% infectivity. Nearly 80% of the infectivity was present in the pellet, while only 3% 
of the infectivity was in the supernatant. Presumably, the decrease in RLuc activity 
between the “Pellet and Supernatant” and “Pellet” samples is due to RVF-VLP loss when 
the media was decanted. 
RVF-VLPs Behave Similar to Authentic RVFV with Respect to Small Molecule Inhibitors 
To determine the feasablity of the RVF-VLPs to function in place of virulent 
RVFV for the screening of RVFV small molecule inhibitors, we tested a panel of small 
molecule inhibitors for activity against RVF-VLPs and RVFV. Two of these compounds, 
ribavirin (60-63) and actinomycin D (64), had previously been tested for activity against 
RVFV and thus serve as positive controls. Ribavirin is a broad spectrum antiviral that is 
believed to inhibit viral replication directly acting on the RdRp or indirectly through 
inhibition of a cellular enzyme necessary for biosynthesis of guanine nucleotides or 
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through the accumulation of mutations and induction of error catastrophe (65-67). 
Actinomycin D was investigated due to its ability to inhibit cellular DNA-dependent 
RNA polymerases but not viral RNA-dependent RNA polymerases (68). Guanidine and 
mycophenolic acid were tested because they have been shown to have activity against 
other RNA viruses. Guanidine is active against the RdRp of poliovirus and many other 
positive-sense RNA viruses (69) and has been also been shown to inhibit the RdRp of a 
dsRNA virus (70). Mycophenolic acid acts on the same cellular enzyme as ribavirin (66, 
71). And finally, monensin and ammonium chloride block the acidification of endocytic 
organelles (72). The acidic organelles are required for membrane fusion for many viruses 
that enter host cells through receptor-mediated endocytosis.  
The inhibitors were added to the cultures at the time of infection with either RVF-
VLPs or RVFV. Infected cells were harvested at 22 h post-infection and minigenome 
activity or expression of N was assayed, respectively. As expected, ribavirin was found to 
be a potent inhibitor of RVF-VLPs (Table 2.2) and RVFV (Fig. 2.9). Mycophenolic acid 
was also a strong inhibitor (Table 2.2, Fig. 2.9), suggesting that inhibition of guanine 
nucleotide biosynthesis is sufficient for inhibition of viral replication. The endocytic 
inhibitors, ammonium chloride and monensin, inhibited both RVF-VLPs (Table 2.2) and 
RVFV (Fig. 2.9), suggesting that the virus enters cells through receptor-mediated 
endocytosis. Guanidine did not strongly inhibit either RVF-VLPs (Table 2.2) or RVFV 
(Fig. 2.9). Actinomycin D blocked activity of RVF-VLPs (Table 2.2) but did not inhibit 
RVFV (Fig. 2.9). Recently, Ikegami et al. discovered the combination of RVFV (MP12 
strain) replication and host transcriptional repression, either by actinomycin D or RVFV 
NSs, was sufficient to induce the activation of protein kinase R (PKR) (46). PKR inhibits 
translation of host and viral proteins, but can be targeted for degradation by RVFV 
NSs (46, 64). The RVF-VLPs do not express NSs, so the induction of PKR by 
actinomycin D cannot be down-regulated. 
Discussion 
In this paper we report on the development of a T7-dependent system for 
production of RVF-VLPs and its application for the high-throughput screening for 
antivirals against RVFV. We generated RVF-VLPs through the expression of a 
minigenome and four viral structural proteins; Gn, Gc, N and RdRp. Although these 
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particles lack the full complement of genomic segments, they behave in a similar fashion 
to authentic RVFV in the four respects tested in this study. (1) RVF-VLPs are able to 
package a minigenome based on the S segment and deliver it to naive target cells. (2) 
RVF-VLPs are secreted from the cell and can be concentrated from the media by 
centrifugation. (3) RVF-VLPs are inhibited from infection of a naive monolayer by 
antibody neutralization using the same set of antibodies that neutralize RVFV. (4) 
Chemical inhibitors of RVFV replication also inhibit RVF-VLPs indicating that the 
minigenome activity is an appropriate surrogate for viral replication.  
Plasmid-based genetic and RVF-VLP systems are powerful tools for studying the 
replicative cycle of viruses. We have modified the design of the T7 RNAP-driven 
plasmid-based rescue system for the virulent ZH-501 RVFV strain (54) to produce RVF-
VLPs capable of performing only a single round of infection. In our design, expression 
plasmids encoding the open-reading frames of the structural proteins were expressed 
along with a minigenome. The expression plasmids do not contain the 5’ and 3’ UTRs 
that have been demonstrated to be required for packaging of the genome (55, 56). Thus, 
the RNAs produced from these plasmids cannot be packaged and these RVF-VLPs are 
capable of only a single round of replication. Using our system, we efficiently generated 
infectious RVF-VLPs. 
Detection of minigenome activity in target cells was robust and did not require 
expression of any RVFV proteins or T7 RNAP. Therefore, RVF-VLPs can be used to 
deliver minigenome to cells that are not efficiently transfected, such as mosquito cells. 
Minigenome activity in RVF-VLP-infected target cells was reduced to near background 
levels by ribavirin, mycophenolic acid, ammonium chloride and monesin, all of which 
were also shown to be active against RVFV. Mycophenolic acid, ammonium chloride and 
monensin had not been tested previously for activity against RVFV. The results obtained 
with ammonium chloride and monensin suggest that RVFV enters cells through receptor-
mediated endocytosis. Our results are the first to examine endocytic entry by RVFV in 
the context of authentic RVFV infection. However, previous studies exploring the ability 
of the RVF envelope glycoproteins to form syncitia using either baculovirus or 
alphavirus-driven expression systems have previously found syncitia formation to be pH 
dependent (73, 74). Interestingly, we saw a differential effect with actinomycin D, in that 
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this compound inhibits RVF-VLPs but not RVFV. Recently it has been shown that NSs 
from either MP12 (vaccine) or ZH-548 (virulent) strains is capable of degrading PKR 
(46, 64). Thus, it is likely that the differential effect we see with actinomycin D is 
because RVF-VLPs do not express NSs. However we cannot rule out the possibility that 
the differential effect of actinomycin D is the result of an inherent difference between 
how infected cells respond to RVFV versus RVF-VLPs. 
Taken together our results strongly suggest that RVF-VLPs can serve as effective 
screening tools for identification of antivirals with activity against RVFV. The RVF-
VLPs obviate the need for operating under select agent guidelines and biosafety level 3 
conditions for agricultural hazards (BSL-3Ag), which would be necessary if using 
virulent RVFV. Our replicon assay produced activity levels 1,500-fold over background, 
while our signal-to-noise values for the minigenome delivered by RVF-VLPs were found 
to be as high as 7,800. Therefore, we have highly sensitive assays for both 
replication/transcription and RVF-VLP infectivity. Additionally, the RVF-VLPs express 
RLuc; thus, they provide a method of determining inhibition in a format that can be 
scaled to high-throughput levels. Furthermore, while the vaccine strain of RVFV (MP12) 
is cytopathic and can be used for high-throughput screening under BSL2 conditions, 
RVF-VLPs have the advantage of allowing for screening for small molecules that inhibit 
discrete viral processes and the ability to identify molecules that increase replication. For 
instance, RVF-VLPs can be used to screen specifically for effects on replication or entry 
into cells, thus making it easier to identify the target of inhibitory or enhancing molecules 
identified in a screen. Additionally, our RVF-VLPs are based on a virulent strain of 
RVFV, thus eliminating the potential of attenuating mutations influencing the activity of 
compounds.  
We are using the RVF-VLP system to study various steps in the RVFV replicative 
cycle, including entry, replication, assembly, and budding. The RVF-VLP system can be 
used to identify the viral proteins and genome elements necessary for the production of 
infectious RVF-VLPs, as well as to elucidate the role of individual protein domains. 
Since expression of N or RdRp in target cells is not required for detection of RVF-VLP 
infection, we can identify protein-protein and protein-RNA interactions that are essential 
to virus assembly through analyzing mutagenesis of all the viral structural proteins. 
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Identification of critical protein domains will allow us to not only screen, but also design, 
small molecule inhibitors targeting these important regions for the development of 
specific therapeutics. 
Materials and Methods 
Plasmids 
The construction of pTrRVFV-SNSs::GFP, pSTrRVFV-NSmM, pN-Amp, and 
pGn/Gc have been described elsewhere (50, 54). pSTrRVFV-SNSs::hRLuc was derived 
from pTrRVFV-SNSs::GFP in several steps. First, the GFP gene was released by 
digestion with EcoRV, followed by ligation with a humanized renilla luciferase gene 
(RLuc) that was flanked by EcoRV sites. The resulting plasmid was then subcloned into 
pSMART HC Kan (Lucigen). pSTrRVFV-SNNSs::hRLuc was derived from 
pSTrRVFV-SNSs::hRLuc by removing the 237 nucleotide SmaI fragment. pRdRp-Amp 
(pSRG309) is derived from the L segment plasmid, pTrRVFV-L (50). In brief, the RdRp 
ORF was amplified from pTrRVFV-L with primers that contained SalI (5’) and NotI (3’) 
sites. The resulting PCR product was then cloned into the SalI/NotI site of pIRES 
(Clontech) and the IRES was subsequently removed by digest of the plasmid with XhoI 
and SalI. The expression plasmids pN and pRdRp were constructed by cloning the open 
reading frames for N and RdRp into pVAX1 (Invitrogen) using HindIII/EcoRI and 
BamHI/NotI sites, respectively. 
Cells and Virus 
Vero E6 and BSR-T7/5 cells were generous gifts from Dr. C. Fulhorst (University 
of Texas Medical Branch, Galveston) and Dr. K. Conzelmann (Max-von Pettenkofer-
Institut, Munchen, Germany), respectively. BSR-T7/5 cells were subsequently cloned by 
limiting dilution and the resulting clonal lines were tested using the RVFV minigenome 
that expresses RLuc. Lines that produced high levels of RLuc from the minigenome were 
expanded. The C3 clone of the BSR T7/5 line was used for all experiments. The BSR-
T7/5 and Vero E6 cells were grown in Dulbecco’s Modified Eagle Medium (Invitrogen) 
supplemented with 10% FCS and sodium pyruvate. The T7 RNAP transgene in the BSR-
T7/5 cells was selected for using 1 mg/mL Geneticin (Invitrogen). The Vero E6 cells that 
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stably express the RVFV RdRp (Vero E6-RdRp) were generated by transfection of Vero 
E6 cells with pSRG309 and pcDNA-Hygromycin (Invitrogen), then selection of 
hygromycin resistant cells with 200 g/mL hygromycin (Invitrogen). The ZH548-MP12 
vaccine strain of RVFV used for all experiments involving infectious virus and was 
obtained from Dr. R. Tesh (World Reference Center of Emerging Viruses and 
Arboviruses). 
Antibodies 
Hybridomas that secrete neutralizing monoclonal antibodies that recognize Gn 
and Gc (R1-4B6-1-2, R1-4D4-1-1 and R5-3G2-1A) and monoclonal antibodies 
recognizing N (R1-P6-F6-6-2-2, R1-P6-F6-10-1-1, R1-P5-A6-12-2-2, RV-V-1B9-1-1, 
R3-1D8-1-2 and RV5-V6E4-1-1) were a generous gift of Dr. G. Ludwig (USAMRIID). 
Polyclonal antibodies that were generated against RVFV in mice were a generous gift of 
Dr. P. Rollin (CDC). Full-length N was expressed with an N-terminal histidine tag and 
purified under denaturing conditions on a Ni-NTA agarose column (Qiagen Inc.). The N 
antibody was generated in rabbits using purified protein as antigen (Harlan Laboratories). 
The secondary antibody used in immunofluorescence experiments was Alexa Fluor 488 
goat anti-rabbit (Molecular Probes). 
Virus-Like Particle Production 
BSR-T7/5 cells were plated at 1 x 10
5
 cells/well in 12-well culture plates. After 
24 h, cells were transfected using 2 L/g TransIT LT1 (Mirus Corporation) and 
plasmids in the ratio 0.25 g minigenome: 0.50 g pN: 0.75 g pRdRp: 0.50 g pGn/Gc. 
Media on transfected cells was replaced every 24 h. Media containing RVF-VLPs was 
typically harvested at 48 or 72 h post-transfection, clarified by low speed centrifugation 
(300 rcf for 10 min at 4˚C) and then diluted prior to being used to infect target cells. For 
some experiments target cells were transfected with pRdRp and pN 24 h prior to 
infection. Target cells were harvested at 24 h post-infection, and were analyzed by either 
fluorescence microscopy or RLuc assay (Promega). For some experiments, RVF-VLPs 
were concentrated. In those cases, clarified media was centrifuged at 82,700 rcf for 4 h at 
4˚C. The supernatant was removed and the pellet was resuspended in complete media. 
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RVFV Inhibitor Screen 
Concentrated stocks of inhibitors were prepared either in water and filter 
sterilized (ribavirin, ammonium chloride, guanidine) or 100% ethanol (monensin, 
mycophenolic acid, actinomycin D). The inhibitors were obtained from Sigma-Aldrich 
(monensin, actinomycin D, guanidine), Calbiochem (mycophenolic acid), VWR 
(ammonium chloride) and RPI Corporation (ribavirin). RVF-VLPs and the ZH548-MP12 
vaccine strain of RVFV (at an MOI of 1) were diluted 1:1 with 2X concentration of 
inhibitors in complete media. After 22 hours incubation, the inhibitors were removed and 
cells were analyzed for RLuc expression (RVF-VLPs) or immunofluorescence 
microscopy (RVFV-infected). 
Immunofluorescence Microscopy 
Cells were plated on glass coverslips and were fixed using freshly prepared 4% 
paraformaldehyde (Sigma-Aldrich) for 30 minutes. The paraformaldehyde was removed 
and cells were washed with PBS containing 1% BSA (PBS/BSA). The cells were 
permeabilized with PBS/BSA containing 0.1% Triton-X100 (Shelton Scientific, Inc.) for 
30 minutes, then washed with PBS/BSA before adding the primary antibody. The 
primary antibody in all experiments was rabbit anti-N. The cells were washed again, and 
the secondary antibody goat anti-rabbit A488 (Molecular Probes) was added and 
incubated in the dark for 1 h. Finally, the cells were washed thoroughly and mounted 
onto glass slides using Prolong Antifade Gold with DAPI (Molecular Probes). The 
fluorescence was visualized using an Olympus BX-51 microscope in the University of 
Michigan Microscopy and Image Analysis Laboratory. 
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Table 2.1. Plasmids used in this study.  
Plasmid name Description Ref 
pTrRVFV-SNSs::GFP S segment-based minigenome plasmid. The 
NSs gene has been replaced with GFP. 
Primary transcription is mediated by T7 
RNAP. Vector backbone derived from pSP64 
(Promega). 
 (54) 
pRdRp RdRp ORF cloned into pVAX1 (Invitrogen). 
Contains T7 RNAP and CMV promoters. 
This study 
pRdRp-Amp (pSRG309) RdRp ORF cloned into pIRES (Clontech). 
Contains T7 RNAP and CMV promoters. 
This study 
pN N ORF cloned into pVAX1 (Invitrogen). 




S segment-based minigenome plasmid. The 
NSs gene has been replaced with hRLuc. 
Primary transcription is mediated by T7 
RNAP. Vector backbone is pSMART HC Kan 
(Lucigen). 
This study 
pSTrRVFV-SNNSs::hRLuc Derived from pSTrRVFV-SNSs::hRLuc, the 
SmaI fragment within the N gene has been 
removed. 
This study 







Figure 2.1. Schematic of RVFV S segment-based minigenome and procedure for generation and 
analysis of RVF-VLPs.  
The minigenome plasmids are derived from the S-segment. The minigenome is flanked by a T7 promoter 
(T7P) and hepatitis delta ribozyme (δRz) and T7 terminator (T7T). T7 RNA polymerase (RNAP) initiates 
transcription at the final G residue in the promoter and terminates at the T7T site. Following transcription, 
the δRz excises itself to generate an authentic viral 3’ terminus. The 5’ and 3’ UTRs are indicated by 
hashed marks and the intergenic region is indicated in black. The S segment is ambisense, and the genes 
illustrated upside-down indicate that they are encoded in the complementary RNA.  Therefore, following 




Figure 2.2.  Internal deletion in N ORF prevents expression from N minigenome. 
BSR-T7/5 cells were either transfected with empty vector (Mock) or transfected with minigenome or ∆N 
minigenome. Cells were fixed 24 h post-transfection and incubated with rabbit anti-N polyclonal antibody, 
followed by Alexa Fluor 488 mouse anti-rabbit secondary antibody. Slides were mounted in Prolong 
antifade with DAPI.  
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Figure 2.3. Schematic of RVF-VLP production. 
Minigenome along with expression plasmids for N, RdRp, and Gn/Gc are transfected into BSR-T7/5 cells. 
The expression constructs have the open reading frames downstream of T7 (T7P) and CMV promoters 
(CMVP) and are followed by polyadenylation signals (pA), generating high-level constitutive expression of 
the genes. The minigenome is first transcribed by T7 RNAP followed by replication and transcription of the 
RNA by the RdRp and N. Transcription of the reporter gene on the minigenome results in production of the 
reporter molecule (RLuc or GFP). Expression of Gn and Gc results in packaging of the minigenome into 
RVF-VLPs that can be harvested and used to infect target cells. In target cells the minigenome is 




Figure 2.4.  Gn/Gc increases RLuc expression in transfected cells. 
BSR-T7/5 cells were transfected with the RLuc minigenome, pN and either empty vector (EV/EV), pRdRp 
and empty vector (RdRp/EV), or pRdRp and pGn/Gc (RdRp/Gn/Gc) and analyzed at the indicated times 






Figure 2.5.  RdRp expression in trans enhances RLuc expression in target cells. 
Media from cell monolayers shown in Figure 2.1 was harvested at the indicated times and used to infect 
untransfected BSR-T7/5 cells, BSR-T7/5 cells that expressed RdRp and N, untransfected Vero cells, or 






Figure 2.6. Infectious RVF-VLPs are efficiently released. 
 (A) Cells were transfected with the GFP minigenome, pN and either empty vector (EV/EV), pRdRp and 
empty vector (RdRp/EV), or pRdRp and pGn/Gc (RdRp/Gn/Gc) and analyzed at the indicated times for 
expression of GFP. (B) Media from cell monolayers shown in (A) was harvested at the indicated times and 




Figure 2.7. RVF-VLPs are neutralized by the same antibodies that neutralize RVFV. 
RVF-VLPs were generated and subjected to a 30 min incubation at room temperature with no antibody 
(Mock), monoclonal anti-N, neutralizing anti-Gn and anti-Gc monoclonals or a polyclonal anti-RVFV 
antibody prior to application on target cells. The antibody concentration effective for neutralization was 
determined on authentic RVFV. The target cells were harvested at 24 h post-infection, and the RLuc 
activity levels were measured. RLuc values (RLU) are expressed relative to the no antibody control. Shown 




Figure 2.8. RVF-VLPs can be harvested using high-speed centrifugation. 
Clarified media from transfected cells was subjected to high-speed centrifugation as described in the 
materials and methods. The “Supernatant”,“Pellet” or “Pellet + Supernatant” were used to infect target 
cells. RLuc activity was measured at 24 h post-infection and is expressed in relative RLuc units. Shown is 
the data for a representative experiment performed in quadruplicate, the error bars reflect the standard 
deviation. 
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Figure 2.9. Effect of small molecule inhibitors on RVFV replication.   
Inhibitors were added at the indicated concentrations at the time of infection with the ZH548-MP12 vaccine 
strain of RVFV at an MOI of 1. At 22 h post-infection, cells were fixed and stained with rabbit anti-N 




Table 2.2.  Effect of chemical inhibitors on RVF-VLP delivered minigenome activity. 
Inhibitors were added at the indicated concentrations at the time of infection with the ZH548-MP12 vaccine 
strain of RVFV at an MOI of 1. At 22 h post-infection, cells were harvested and analyzed for RLuc 
activity. 
Inhibitor Concentration % Activity 
 Mock (water) - 100 
Ammonium chloride 5 mM 9.7 
 10 mM 1.3 
 20 mM 0.5 
Guanidine 25 g/mL 45.8 
 50 g/mL 19.2 
 100 g/mL 22.4 
Ribavirin 25 g/mL 12.8 
 50 g/mL 6.2 
 100 g/mL 4.3 
Mock (ethanol) - 100 
Actinomycin D 0.5 g/mL 13.2 
 1.0 g/mL 6.4 
 2.0 g/mL 5.2 
Monensin 0.1 M 58.2 
 1.0 M 2.1 
 10.0 M 0.2 
Mycophenolic acid 1.0 M 48.6 
 10.0 M 8.9 
 100.0 M 5.8 
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Chapter 3  
 
Structure of the Rift Valley Fever Virus Nucleocapsid Protein Reveals a New 
Architecture for RNA Encapsidation 
Introduction 
RNA viruses are responsible for a myriad of human and animal diseases, 
including measles, polio, rabies, the common cold, dengue fever, and Rift Valley fever.  
Despite tremendous diversity among RNA viruses, all must package a protected RNA 
genome into virus particles.  RNA viruses protect their genome in one of two ways, 
providing either a protein shell or a protein coat for the genome (75).  The process is 
generally known by the term encapsidation, however functionally and structurally 
encapsidation takes a variety of forms.  Most positive-sense RNA and double-stranded 
RNA viruses place their genome within a protein shell, known as a capsid.  By contrast, 
the negative-sense RNA viruses encapsidate their genome by coating the length of the 
RNA with a nucleocapsid protein (N).  Although capsid and N all bind RNA, the 
resulting RNA-protein complexes differ, and it is not possible to make generalizations 
about the proteins involved in encapsidation across all RNA virus families. 
Rift Valley fever is a mosquito- and aerosol-borne disease of livestock and 
humans in sub-Saharan Africa, and is caused by Rift Valley fever virus (RVFV).  Rift 
Valley fever in domestic ruminants results in abortion and high rates of mortality, 
especially among young animals (29, 32).  In humans, Rift Valley fever is typically a 
self-limited febrile illness, although severe disease, such as hemorrhagic fever and 
encephalitis, occurs in a small percentage of cases (29, 31, 32).  RVFV has a membrane 
envelope and a genome comprised of three negative-sense RNA segments, termed small 
(S), medium (M) and large (L) (40).  It belongs to the Phlebovirus genus in the 
Bunyaviridae family.  As with all negative-sense RNA viruses, the genome is bound, or 
encapsidated, by N.  The N of RVFV is a 27-kDa protein encoded by the S segment. 
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Bunyavirus N binds single-stranded RNA (ssRNA) non-specifically (76-78), 
although some N may have a preference for specific viral RNA sequences (78-83).  
Studies on some animal viruses within the Bunyaviridae family found that encapsidated 
RNA is resistant to disruption by high salt and RNase treatment (78, 80, 82).  
Despite the common property of tight, non-specific binding to single-stranded 
RNA, homology of N within the Bunyaviridae family is not apparent from sequence data, 
as N from different genera appear unrelated.  However, within a genus, the N are clearly 
homologous.  When RVFV N is compared across the Phlebovirus genus, the amino acid 
identity generally ranges from 50% to 59%, and is 36% for Uukuniemi virus, the most 
divergent clade within the Phlebovirus genus.  The high degree of sequence identity 
indicates that the phlebovirus N have similar structures and likely bind RNA in a similar 
fashion.  Additionally, the phlebovirus N are distantly related to the N of the Tenuivirus, 
a genus of negative-sense RNA viral plant pathogens with worldwide distribution (84).  
Otherwise, by sequence analysis, the phlebovirus N appear unrelated to N of other 
negative-sense RNA viruses. 
Encapsidation of RVFV genomic RNA, as with all negative-sense RNA viruses, 
plays an essential role in multiple steps within the replicative cycle including 
transcription and replication by the RNA-directed RNA polymerase (RdRp)(57, 85), and 
packaging of genome into virions (40). RVFV N is thought to interact with the viral 
RdRp because N is essential to replication and transcription (40).  N also plays a role in 
virus assembly through interactions with the viral envelope glycoproteins (GN and GC) 
(86).  Structural information is essential to understanding how N participates in these 
critical processes.  
Crystal structures are available for N from several negative-sense RNA viruses, 
including influenza A virus (FLUVA (87)), rabies virus (RABV (88)), human respiratory 
syncytial virus (HRSV (89)), vesicular stomatitis virus (VSV (90)) and Borna disease 
virus (BDV (91)).  For some of these, ribonucleoprotein (RNP) complexes have been 
visualized by crystallography or electron microscopy (FLUVA (92), RABV (88), HRSV 
(89), VSV (90)).  The RNP complexes are high-order ring structures in which loops or 
chain termini of N make specific contacts with neighboring N subunits, leading to a 
condensed structure for the encapsidated genome.  In contrast to these viruses, 
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encapsidated bunyavirus genomes have a non-condensed, macro-circular form, based on 
low-resolution images (93, 94).  None of the structurally characterized N is from the 
Bunyaviridae family and none has detectable homology with the phlebovirus N.   
Here we report the characterization and crystal structure of recombinant RVFV N.  
The protein was purified under denaturing conditions.  The re-folded N forms RNA 
complexes similarly to N from virus-infected cells.  The 1.93-Å crystal structure of 
RVFV N reveals a novel protein fold that differs substantially from N of other negative-
sense RNA viruses.  A dimeric association of N subunits appears critical to its function.  
A conserved electropositive surface is proposed as the site of RNA binding. 
Results  
Protein oligomeric state in solution 
Purification of recombinant N (recN) under native conditions, including 
exhaustive ribonuclease treatment, resulted in a discrete complex of the protein and E. 
coli nucleic acid as determined by the ratio of absorbances at 260 nm and 280 nm. 
Attempts to separate the protein from nucleic acid under native conditions using high salt 
concentrations and pH extremes were unsuccessful.  The complex had an apparent mass 
of 99 kDa by size exclusion chromatography, which is similar to the 109-kDa species 
observed for the recombinant 27-kDa N of bunyamwera virus, from the Orthobunyavirus 
genus of the Bunyaviridae family (76). Nucleic acid was extracted from the recombinant 
RVFV N by denaturation and then treated with either DNase or RNase.  The purified 
nucleic acid was sensitive only to RNase treatment, demonstrating that N was bound to 
RNA (Fig. 3.1A).  The majority of the RNA purified was 30-35 nucleotides with minor 
species of ~60 and ~90 nucleotides (Fig. 3.1B, asterisks).  The formation of a nonspecific 
ribonucleoprotein (RNP) complex between recombinant RNA-binding proteins and E. 
coli RNA is not uncommon (76, 89, 95).  Indeed crystal structures of RABV (88), VSV 
(90) and HRSV (89) RNPs were solved from RNPs bound to E. coli RNA, however no 
crystals were obtained using the recombinant RVFV RNPs.  We therefore used 
denaturation to obtain RNA-free recN.  After purification from RNA and refolding, the 
protein eluted from a size-exclusion column primarily as a monomer, with about 10% 
apparently as a dimer under chromatographic conditions (Fig. 3.2).   
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Authentic virus RNPs and purified recombinant N bound to RNA form similar multimeric 
complexes 
We tested whether the refolded recN could interact with RNA similarly to N in 
viral RNPs. Purified viral RNPs, refolded recN, and refolded recN with added RNA 
(recN-RNA) were subjected to cross-linking using the homo-bifunctional amine-reactive 
cross-linker, dithiobis[succinimidyl propionate] (DSP), and then separated by 
electrophoresis under denaturing conditions (Fig. 3.3).  In the absence of cross-linker 
(Fig. 3.3A, lane 1; Fig. 3.3B, lanes 4 and 9), recN migrated as a monomer, regardless of 
the presence of RNA.  When viral RNPs were cross-linked with increasing amounts of 
DSP, the monomer band decreased in intensity and four higher molecular weight 
complexes appeared (Fig. 3.3A, lanes 2 and 3).  The number of N within the dominant 
cross-linked species was estimated to be 2, 4, 6, and 10 based on an apparent molecular 
weight per monomer of 25 kDa.  When RNA-free, re-folded recN was cross-linked with 
increasing concentrations of DSP, only two species were observed (Fig. 3.3B, lanes 5-8).  
The higher molecular weight species was estimated to contain two N (Fig. 3.3B, lane 5). 
The cross-linked dimer and its low concentration relative to the monomer are consistent 
with the predominant monomeric and minor dimeric species observed by size exclusion 
chromatography for refolded recN (Fig. 3.2).  In contrast, when recN-RNA was cross-
linked with DSP, many species of higher molecular weight were observed (Fig. 3.3B, 
lanes 10-13).  The number of N within the dominant cross-linked species created from 
recN-RNA (Fig. 3.3B, lane 11) was estimated to be 2, 4, 6, and 10.  The sizes of the high 
molecular weight N complexes were similar regardless of whether the cross-linked 
sample contained viral RNP or reconstituted recN-RNA.  Thus, refolded recN behaves 
similarly to viral N in its ability to bind RNA and to form multimeric complexes.  
Interestingly, the cross-linked species formed by both viral RNPs and recN-RNA appear 
primarily as multiples of 2, suggesting that N binds RNA as a dimer. 
Overall structure 
Recombinant, RNA-free RVFV N was crystallized and the structure was solved 
by multiwavelength anomalous diffraction from the selenomethionyl (SeMet) protein 
(Table 3.1).  The crystals contained four N polypeptides in the asymmetric unit of space 
group P1, affording four independent views of the structure.  The four copies of the N 
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polypeptide are nearly identical with root-mean-square-deviations (RMSD) of 0.46 Å for 
238 C atoms.  The refined structure is complete with the exception of residues 16-19 
and 28-30.  In these regions, each of the four polypeptides lacks density for one, four or 
seven amino acids. 
RVFV N has a compact, helical fold consisting of N-terminal and C-terminal 
lobes of approximately equal size, connected by a linker helix (7, residues 112-121) 
(Fig. 3.4).  Both the N-lobe (1-6, residues 1-111) and the C-lobe (8-12, residues 
122-245) have a central helix (3 and 9) surrounded by four or five other helices.  
Despite these similarities, the topologies differ and the N- and C-lobes cannot be 
superimposed. We examined the structural database for proteins with folds similar to 
RVFV N.  Remarkably, the folds of both the N- and C-lobes appear to be novel.  No 
structure similar to either lobe was identified in searches with the servers Dali (96) and 
VAST (97).  
The crystallized protein includes the full natural sequence (Met1-Ala245) without 
additional residues.  Both chain termini are well ordered (Fig. 3.5).  Met1 makes intra- 
and intermolecular contacts with hydrophobic residues in helix 1 (residues 3-10).  The 
C-terminal α-carboxyl of Ala245 forms a salt bridge with the Arg178 side chain.  Neither 
of the chain termini nor any loops protrude from the protein. 
RVFV N crystallized as a symmetric dimer (Fig. 3.6A).  We conclude that this is 
a natural dimer because the crystal contains two independent copies of the dimer, which 
are nearly identical (RSMD of 0.48 Å for 476 Cα atoms), and because we observed 
dimers of RNA-free N in solution (Fig. 3.2, 3.3).  As expected for a natural dimer, the 
subunit interface is hydrophobic and lacks buried water.  The small interface (502 Å
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buried surface area per monomer) is consistent with the low proportion of dimeric 
relative to monomeric species of RNA-free N observed by gel filtration (Fig. 3.2).  The 
dimeric species is expected to predominate in crystals where the protein concentration is 
higher than in solution.  The dimer is formed by contacts of residues in helices α1, α7 
and α8.  The side chain of Trp125 (α7-α8 loop) is buried in the dimer interface where 
it contacts the side chains of Met1, Gln5, Ile9 and Trp125 in the second monomer (Fig. 
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3.6).  Ala12, Val120, Val121, Glu124 and Thr131 also form inter-subunit van der Waals 
contacts. 
Comparison with N of other negative-sense RNA viruses 
Given the rapid rate of virus divergence, we anticipated that the phlebovirus N 
might resemble the N of other negative-sense RNA viruses even though the sequences 
are dissimilar.  Two different folds for N have been reported, one for FLUVA (87) in the 
family Orthomyxoviridae, and the other for four viruses in the order Mononegavirales 
(RABV (88), VSV (90), HRSV (89) and BDV (91)).  However, the phlebovirus N fold 
differs from both these other N folds.  Thus at least three different folds exist for N of the 
negative-sense RNA viruses.  Intriguingly, all three folds are predominantly helical and 
are bi-lobed.  However, the phlebovirus N has a more compact structure.  RNA binds in a 
deep, positively charged cleft between the two lobes of N from both the Mononegavirales 
and FLUVA N (88-92).  Phlebovirus N lacks a cleft between the N- and C-lobes (Fig. 
3.4). Another important difference is the lack of protrusions in phlebovirus N.  The N- 
and C-termini of N of the Mononegavirales protrude from the subunit, as does an 
extended loop in the N of FLUVA.  These protrusions contact other N subunits and are 
important to the structure of the RNP (88-92).   
Conservation of Phlebovirus N  
Sequences of N from phleboviruses are highly conserved (Fig. 3.7), with at least 
41% pairwise sequence identity among 30 representative phleboviruses (excluding the 
divergent Uukuniemi clade, whose N is 35% identical to RVFV N).  The 66 invariant 
residues map primarily to the core of the structure, suggesting that they are important for 
conservation of the overall fold (Fig. 3.8A).  Residues in the dimer interface are not 
strictly conserved. However, the dimer contact appears to be present in all phlebovirus N 
because compensatory sequence changes accommodate the size and hydophobicity of the 
residue corresponding to Trp125.  For example, if the residue at position 125 (Trp in 
RVFV N) is aromatic, then the residue at position 12 (Ala in RVFV N) has a small side 
chain such as glycine, serine or alanine (Fig. 3.7).  However, if the residue at position 125 
has a smaller side chain such as serine, then the residue at position 12 is correspondingly 
larger (leucine). The structure and sequence alignment are consistent with published 
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mutagenesis data suggesting that the N-terminus of RVFV N is required for dimer 
formation (98).  However, the conserved residues tested in the previous study (Tyr4, 
Phe11) are not in the dimer interface. Instead they point away from the dimer interface 
towards the inside of the monomer where they form stabilizing contacts in the 
hydrophobic core of the protein.  The observed loss of function of Tyr4Gly and 
Phe11Gly (98) is likely due to destabilization of helix 1 (residues 3-10) and, indirectly, 
the dimer interface.  
Trp125 in the dimer interface and C-terminal salt bridge are required for N function 
The structure suggests that Trp125 is critical for dimer formation because of the 
hydrophobic contacts it makes with Met1, Ile9 and Trp125 of the opposing N monomer.  
Additionally, a salt bridge between the C-terminal carboxyl group of Ala245 and the 
Arg178 side chain, which is Arg or Lys in all phlebovirus N, may be important for 
overall structural integrity.  To test these predictions, three mutant N alleles were 
generated, Trp125Ala, Arg178Gln and Arg178Glu, and the function of these alleles was 
analyzed in a cell-based RdRp transcription assay. In the transcription assay, RdRp and N 
are expressed from separate plasmids.  When RdRp and N were both present and 
functional, a luciferase mRNA from a recombinant S segment is transcribed (Chapter 2). 
The Trp125Ala allele was severely compromised and activity was only 4% of the wild 
type allele (Table 3.2).  This result suggests that dimer formation is essential for activity, 
presumably because N binds RNA as a dimer.  If the salt bridge of Arg178 with the C-
terminus is critical, then the Arg178Gln allele should retain more function than the 
Arg178Glu allele, and this was the observed result (Table 3.2).  The activity of the 
Arg178Gln and Arg178Glu alleles was 25% and 7% of wild type, respectively.  All 
alleles expressed protein at a level similar to wild type and all appeared capable of 
forming higher molecular weight complexes with RNA (Fig. 3.9).  Presumably, the 
defect lies in either the efficiency of binding RNA or possibly in the stability of N 
dimers. 
RNA binding 
Consistent with the high affinity for RNA, RVFV N is positively charged with a 
calculated isoelectric point of 9.1.  We considered whether there is an obvious RNA-
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binding surface on the RVFV N dimer.  A map of the electrostatic surface potential 
revealed two positive patches that are candidate RNA binding sites (Fig. 3.10A).  One 
positive patch crosses the dimer axis on a convex surface we designate “front”.  A cleft at 
the dimer interface on the “back” of the dimer lacks a positive patch.  A second patch 
maps to one “side” of each monomer, resulting in positive patches on both sides of the 
dimer.   
As N from related phleboviruses share high sequence identity, they are likely to 
bind RNA similarly.  We generated structure-based homology models for four N that 
represent clades within the Phlebovirus genus, calculated the electrostatic surface 
potentials (Fig. 3.11), and also mapped conservation onto the RVFN surface (Fig. 3.10B).  
The positive patch on the convex front surface of the RVFV N dimer is not conserved 
across the Phlebovirus genus and is negatively charged in some phlebovirus N (Fig. 
3.11).  In contrast, a positive patch is present on the sides of all the modeled phlebovirus 
N.  Thus, RNA may bind in the positively charged surfaces on opposite sides of the N 
dimer.  The most strongly conserved surface on Phlebovirus N is at the “top” and 
“bottom” of the dimer.  The conserved surface is a hydrophobic pocket formed by a loop 
between residues 27-35 and the C-terminal half of α10 along with the 5 succeeding 
amino acids (residues 198-210) (Figs. 3.10B and 3.11), which include the most mobile 
regions of the N structure (Fig. 3.8B).  The combination of mobility, conservation and 
hydrophobicity suggest that this site may be involved in a conserved protein-protein 
interaction. 
Discussion 
The structure of RVFV N is the first for a nucleocapsid protein from any virus in 
the Bunyaviridae family.  The structure reveals a new protein fold and an addition to 
nature’s repertoire of RNA-binding proteins.  The sequence of RVFV N is 36-59% 
identical to those of other phleboviruses, and aligns largely without internal gaps.  Such 
high sequence identity assures that the new fold observed for RVFV N exists in all 
phlebovirus N, and also suggests that all phlebovirus N bind RNA similarly. 
This work establishes a fundamental dimeric form of RVFV N.  In RNPs 
extracted from the virus, the dimer was observed in a ladder of cross-linked species of N 
(Fig. 3.3).  The dimer was also observed in the recombinant and refolded N by cross-
44 
linking in presence of RNA to a similar ladder of species (Fig. 3.3B), by cross-linking to 
a dimeric species in absence of RNA (Fig.3.3B), by gel filtration (Fig. 3.2), and in the 
crystal structure (Fig. 3.6).  The functional significance of the dimer was corroborated by 
site-directed mutagenesis of Trp125 in the center of the dimer interface (Fig. 3.6).  
Substitution of Trp125 by Ala severely compromised transcription by the RdRp.  
Although it did not alter the level of N in cells or affect the formation of cross-linked 
species in vitro (Table 3.2, Fig. 3.9), the Trp125 mutation may affect the stability of N 
dimers.  Taken together, the data indicate that the N dimer is critical to RdRp 
transcription, that it may be the fundamental unit of nucleocapsid assembly, and that it 
forms higher-order species in the presence of RNA.   
The minimal higher-order species is the RNase-resistant multimer of apparent 
molecular weight 99 kDa (Fig. 3.2).  This species may be a dimer of dimers, or it may be 
one dimer with a hydrodynamic radius expanded by RNA.  It is similar to the reported 
109-kDa recombinant RNP from Bunyamwera virus, which was predicted to be a 
tetramer of N (27 kDa) bound to ~48 RNA nucleotides (76).  Bunyamwera virus and 
RVFV belong to different genera within family Bunyaviridae and their N are not 
obviously similar at the amino acid level.  Nevertheless the existence of similar 
multimeric species suggests that the bunyavirus N may fold and bind RNA similarly.  
An electropositive surface on RVFV N was identified as a potential RNA 
interaction site because it appears to be positively charged in N from all phlebovirus 
clades.  The surface is on the “side” of the N monomer and maps to both sides of the 
dimer by symmetry (Figs. 3.10 and 3.11).  This is consistent with a model in which RNA 
wraps around the N dimer in nucleosome fashion.  Neither the position of the conserved 
electropositive surface on opposite sides of the N dimer nor the electrostatic potential of 
other surfaces suggests an obvious structure for a stable RNA complex with two N 
dimers, but certainly does not rule out such a possibility.  In whatever manner N binds 
RNA, it is expected to engage the phosphate backbone because the multimer is so highly 
RNase resistant.  All negative-sense RNA viruses form RNPs in order to protect and 
package their genome.  Many of these RNPs are RNase-resistant structures formed by 
oligomers of N associated with RNA that resemble beads on a string and in some cases 
assemble into higher-order structures with helical symmetry (40).  Our results indicate 
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that phlebovirus RNP has a fundamentally different higher-order structure than has been 
observed for RNPs from other negative-sense viruses. 
The structures of RNPs from four negative-sense RNA viruses from the 
Paramyxoviridae, Rhabdoviridae, and Orthomyxoviridae families have been reported 
(88-90, 92).  In all cases, RNA binds nonspecifically in an electropositive cleft between 
the lobes of the N subunit.  The RNPs have a similar architecture in which RNA binds 
around either the outside or inside of a ring of 9-11 N subunits.  In all cases, protrusions 
from the N subunits make specific contacts with adjacent N subunits to maintain the ring 
structure.  For HRSV, each N subunit also interacts with other N subunits in the 
preceding or following turns of the helical nucleocapsid (89). 
The RNP of Phleboviruses, and perhaps all bunyaviruses, clearly has a different 
organizing principal than the RNPs of theviruses of the Mononegavirales order and 
Orthomyxoviridae family.  Early electron microscopy studies suggested that the RNPs 
from bunyaviruses form large macro-circles (93, 94), probably due to pairing of 10-15 
complementary bases at the 3' and 5' ends of each genomic segment (99).  Although the 
lack of obvious superhelical periodicity in bunyavirus RNPs could be an artifact of the 
negative staining used in these experiments, it is consistent with the crystal structure of 
Phlebovirus N.  The Phlebovirus N monomer lacks a cleft between lobes, and there is no 
electropositive cleft between subunits of the dimer (Fig. 3.11).  More important, the 
highly compact Phlebovirus N structure has no protruding hooks that could link it to 
other N molecules in a super-structure like the rings of 9-11 subunits observed for the 
Mononegavirales order and Orthomyxoviridae family.  Indeed, we observed no such 
super-structure for recombinant RVFV N in solution, unlike the recombinant rings 
purified for N from HRSV (89) and FLUVA (92).  Thus, we suggest a simple string-of-
beads architecture for phlebovirus RNP, based on the preponderance of data. 
The most strongly conserved surface of phlebovirus N is a hydrophobic pocket at 
the top and bottom of the dimer (Fig. 3.8A and 3.10).  The conservation in this region 
suggests it has an important function that is common to phleboviruses, and the 
hydrophobicity of the surface suggests that it is not involved in RNA binding.  Therefore 
we propose that this is the site of a conserved protein-protein interaction.  It is possible 
that an unidentified host protein interacts with this site on N.  Among potential viral 
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protein partners, the RdRp is an obvious possibility because N is required for 
transcription and replication by the RdRp (40).  However, several lines of evidence 
suggest that an envelope glycoprotein may be the target of the conserved hydrophobic 
pocket on N. 
 Packaging of RNPs into virions occurs at a site of virus assembly on the Golgi 
membrane (100, 101) and is thought to involve contact between N and the cytosolic 
region(s) of one or both of the envelope glycoproteins (GN and GC).  The GN cytoplasmic 
tail was shown recently to recruit the encapsidated genome to the Golgi membrane prior 
to virion assembly (86, 102) (Chapter 4).  Moreover, the encapsidated genome of RVFV 
interacts with a 30-residue domain on the C-terminal cytoplasmic tail of GN immediately 
downstream of the transmembrane domain (Chapter 4).  Since the recruitment of the 
genome is expected to be similar in all phleboviruses, the conserved hydrophobic pocket 
of N is a candidate GN binding site.  This hypothesis is consistent with the ability of 
bunyaviruses to undergo reassortment of genomic segments both in nature and in vitro 
(13-15).  The progeny of a reassortment event have genomic segments that derive from 
more than one parental virus.  Thus, there must be a certain amount of promiscuity in the 
interaction of N with genomic RNAs from heterologous viruses and in protein-protein 
interactions necessary for assembling virions.  All characterized reassortant bunyaviruses 
isolated in nature are M segment reassortants (10, 12, 17), demonstrating that the 
envelope glycoproteins, which are encoded by the M segment, are capable of interacting 
with heterologous RNPs. The hydrophobic character of the GN-tail interaction domain, as 
well as certain Pro and Trp residues within it, are conserved amongst phleboviruses (50) 
and could function in protein-protein interactions with N in both pure and reassortant 
viruses.  Thus the conserved pocket in N may be an interacting surface for the 
cytoplasmic tail of GN.  Whether the conserved pocket of N interacts with the GN 
cytoplasmic tail, with the RdRp or with a host protein, it has potential as a drug target 
because it is conserved in phleboviruses. 
The structure and characterization of Phlebovirus N reveal a new paradigm for 
encapsidation of the genomes of negative-sense RNA viruses, provide a platform for 
further studies of virus pathogenicity, and suggest a potential site for development of 
effective antiviral therapeutics. 
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Materials and Methods 
Plasmids 
All plasmids were generated using standard molecular cloning techniques and 
were confirmed by sequencing.  pTrRVFV-SNSs::GFP, pRdRp-Amp and pN-Amp 
have been described previously (50, 54).  To generate the protein expression construct for 
N, the gene was amplified using Phusion polymerase (New England Biolabs), pTrRVFV-
SNSs::GFP as template, and primers 5’-
GACGTGGGTCTCGAGGTATGGACAACTATCAAGAGCTTG-3’ and 5’-
CTCGAGTTAGGCTGCTGTCTTGTAAGCCTG-3’.  The PCR product was cloned into 
pCRII-Blunt-TOPO (Invitrogen).  Digestion with BsaI and XhoI liberated the N ORF, 
which was subsequently ligated into pSUMO (Life sensors, Inc.), thus producing 
pIPER1.  For the RdRp transcription assay, the plasmids pN and pRdRp were constructed 
by subcloning the open reading frames from pN-Amp and pRdRp-Amp into pVAX1 
(Invitrogen) using the HindIII/EcoRI and BamHI/NotI sites, respectively.  pSTrRVFV-
SNSs::hRLuc was derived from pTrRVFV-SNSs::GFP in several steps.  First, the 
GFP gene was released by digestion with EcoRV, followed by ligation with a Renilla 
luciferase gene that was flanked with EcoRV sites.  The resulting plasmid was then 
subcloned into pSMART HC Kan (Lucigen). pSTrRVFV-SNNSs::hRLuc was derived 
from pSTrRVFV-SNSs::hRLuc by removing the 237 nucleotide SmaI fragment from 
the N gene. The RVFV N mutants, W125A, R178Q, and R178E, were generated using 





CTGCAGTTCTCCGAGGTCATCAACCCA -3’ and 5’-
TGGGTTGATGACCTCGGAGAACTGCAG-3’, respectively.  
Cells and virus 
BSR-T7/5 cells expressing the T7 RNA polymerase were a generous gift of Dr. 
K. Conzelmann (Max-von Pettenkofer-Institut, Munchen, Germany). BSR-T7/5 cells 
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were subsequently cloned by limiting-dilution, and the resulting clonal lines were 
screened using the RVFV transcription assay. The C3 clone of the BSR T7/5 line was 
used for all experiments. The cells were grown in Dulbecco’s Modified Eagle Medium 
(Invitrogen) supplemented with 10% fetal calf serum, and 1 mg/mL geneticin.  RVFV 
ZH548 MP12 vaccine strain was a generous gift of Dr. R. Tesh (World Reference Center 
of Emerging Viruses and Arboviruses). 
Production and purification of recombinant N 
pIPER1 was transformed into E. coli strain BL21 AI (Invitrogen) containing the 
pRARE2 plasmid (Novagen) (103) and grown in 1 L of TB media (12 g tryptone, 24 g 
yeast extract, 2.31 g KH2PO4(monobasic), 12.5 g K2HPO4 (dibasic), 40 mL glycerol) 
containing 35 µg/mL chloramphenicol and 50 µg/mL kanamycin at 37˚C until 
OD600=1.0. The temperature was reduced to 20˚C, and expression was induced after 1 hr 
by addition of 4 mL 50% w/v arabinose and isopropyl-β-D-thiogalactopyranose (IPTG) 
to a final concentration of 0.4 mM. The cultures were incubated 12 hr at 20˚C and cells 
were harvested by centrifugation. All purification steps were carried out at 4˚C unless 
otherwise noted. 
Initial attempts to purify the recombinant protein under native conditions resulted 
in protein bound to heterologous E. coli RNA, so the protein was purified under 
denaturing conditions and refolded (95). Briefly, cell pellets were resuspended in 35 mL 
lysis buffer (50 mM Na-phosphate pH 7.8, 1 M NaCl, 20 mM imidazole, 5% glycerol), 
lysed by sonication, and centrifuged at 27,000 x g for 45 minutes. The supernatant was 
loaded onto a 5-mL HiTrap chelating column (GE Healthcare) pre-equilibrated with lysis 
buffer. After a wash with 10 column volumes of lysis buffer, the protein was unfolded 
with a linear gradient of 0-8 M urea in lysis buffer over 5 column volumes. After a wash 
with 5 column volumes of lysis buffer with 8 M urea, the protein was refolded with a 
linear gradient of 8-0 M urea in lysis buffer over 10 column volumes followed by a wash 
with 10 column volumes of lysis buffer. The protein was eluted with a linear gradient of 
20-500 mM imidazole in lysis buffer.  Fractions containing SUMO-N, as determined by 
12% SDS-PAGE, were pooled and dialyzed 1 hr against 1 L dialysis buffer (50 mM Na-
phosphate pH 7.8, 1 M NaCl, 5% glycerol). SUMO-protease was added to a final 
concentration of 1:1000 (protease:protein) and dialysis was continued with fresh buffer 
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for 16 hr. The expression plasmid for SUMO protease was a kind gift of C. Lima, 
Memorial Sloan-Kettering Cancer Center (104). The proteolysis mixture was loaded on a 
5-mL HiTrap column pre-equilibrated with lysis buffer, and cleaved protein was washed 
from the column with lysis buffer. N was concentrated using Centriprep-10 (Millipore), 
and subjected to size exclusion chromatography by a HiLoad 16/60 Superdex 75 gel 
filtration column (Amersham) pre-equilibrated with storage buffer (20 mM TRIS pH 7.8, 
0.5 M NaCl, 10% glycerol). The fractions corresponding to the N monomer peak were 
pooled and concentrated to 13 mg/mL using Centriprep-10. Purified protein was flash-
frozen in liquid N2 and stored at -80˚C. Typical 1-L cultures yielded 20 mg of purified, 
refolded N.  
To produce the selenomethioninyl (SeMet) variant of N, 50-mL cultures were 
grown in rich media and cells were harvested and added to SelenoMet Medium Base 
supplemented with SelenoMet Nutrient Mix (Athena Enzyme Systems) and 100 mg/L of 
D,L-SeMet to give an initial OD600 of 0.3.  Cultures were grown to OD600=0.5, incubated 
1 hr at 20˚C, and induced with 0.4 mM IPTG.  SeMet N was purified identically to the 
wild type. 
Crystallization 
Prior to crystallization, N was dialyzed against crystallization buffer (20 mM Tris 
pH 7.8, 250 mM NaCl).  N was crystallized at 4˚C by hanging drop vapor diffusion from 
a 1:1 mixture of protein (10 mg/mL N in crystallization buffer) and well solution (26% 
PEG 3350, Na/K phosphate pH 5.5).  Optimal crystals were obtained after 2 weeks.  The 
crystals were cryo-protected by soaking in well solution with the addition of 10% 
glycerol, harvested into loops, and frozen by plunging into liquid N2. 
Crystallography 
Diffraction data were collected at 100 K on GM/CA-CAT beamline 23ID-D 
(native) and 23ID-B (SeMet) at the Advanced Photon Source (APS), Argonne National 
Laboratory (Argonne, IL).   
Although the crystals appeared single, all diffracted in two lattices, which 
complicated data processing.  The SeMet data were processed using HKL2000 (105), 
with which images could be indexed on the stronger lattice by using only data beyond 4-
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Å spacings for initial indexing.   Data from crystals of wild type N were processed with 
iMOSFLM (106), which was able to index with no exclusions.  SOLVE (107) and 
RESOLVE (108) were used for initial phasing using a two-wavelength MAD data set 
from one crystal of SeMet protein.  36 of the 48 Se sites were located and used for MAD 
phasing (phasing-power = 0.9, initial FOM = 0.35), followed by density modification 
phase refinement with four-fold averaging and automated modeling (60% of main chain) 
in phenix (109).  Modeling was completed manually using COOT (110) and refinement 
was performed using REFMAC5 (111) of the CCP4 suite (112).  The structure was 
solved from triclinic crystals with four N polypeptides in the asymmetric units.  The final 
model is complete except for residues 17 in chain A, 18 in chain B, 16-19 in chain C, and 
16-19 and 28-30 in chain D.  All residues are in favored regions of the Ramachandran 
plot except for Ile209 in all four chains, which is well supported by density. The structure 
was validated using MolProbity (113), PyMOL was used for generating figures and for 
molecular superpositions (114), sequence alignments were done using ClustalW (115), 
the apbs plugin in PyMOL was used to calculate electrostatic surface potential (116), and 
ESPript (117) was used for secondary structure assignment. Structure based homology 
models were generates using the MMM server (118) and optimized using YASARA 
(http://www.yasara.org).  Conservation scores were calculated by the ConSurf server 
(119). 
RNP preparation  
Encapsidated genomes or ribonucleoparticles (RNPs) were purified from Vero E6 
cells infected with RVFV MP-12 strain.  Cells and supernatants were harvested when 
cells started to show cytopathic effect and frozen at -80˚C.   The cell slurry was thawed 
on ice and octyl--D-glucopyranoside was added to a final concentration of 1%, and the 
mixture was incubated on ice for 1 h.  Insoluble material was removed by centrifugation 
at 1,100g for 15 min at 4˚C. The supernatant was then centrifuged at 53,000g in an SW28 
rotor for 8 h at 4˚C.  The pellet was resuspended in 1X TNE (10 mM Tris, pH 7.5, 100 
mM NaCl, 1 mM EDTA) with 5% sucrose.  The soluble material was then layered on top 
of a 30-50% CsCl gradient that was then subjected to centrifugation at 53,000 x g in an 
SW28 rotor for 16 h at 4˚C.  Fractions were taken from the bottom of the gradient and 
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analysed for the presence of N by ELISA.  Fractions containing N were pooled and 
analyzed by SDS-PAGE followed by colloidal Coomassie staining. 
Antibodies 
The N antibody was generated in rabbits using purified and denatured N as 
antigen (Harlan Laboratories).  The horseradish peroxidase conjugated anti-rabbit 
antibody was obtained from Amersham.  
Cross-linking 
For cross-linking, a reconstituted RNP (N-RNA) was generated by incubating 
refolded recombinant N (recN) with a 25-nucleotide polyU RNA oligomer for 30 minutes 
at a ratio of 6:1 recN:RNA.  The sample was then run on an S200 size exclusion column 
to separate N-RNA from RNA-free recN. The recN and N-RNA were dialyzed against 
PBS to remove the Tris storage buffer prior to incubation with DSP. Purified recN, N-
RNA, or purified viral RNPs (vRNP) were cross-linked by incubating 30 g of recN at a 
concentration of 1 mg/mL, or purified vRNPs with 0.0, 1.0, 5.0, 10.0 or 20.0 M 
dithiobis[succinimidyl propionate] (Pierce) for 15 minutes at room temperature.  The 
cross-linking was quenched by addition of Tris pH 6.7 to a final concentration of 100 
mM.  Protein complexes were analyzed by SDS-PAGE followed by either colloidal 
Coomassie stain or western blot using a polyclonal rabbit anti-N antibody.   
RVFV transcription assay 
BSR-T7/5 cells were plated at 1x10
5
 cells/well in 12-well culture plates.  After 24 
h, cells were transfected using 2 L/g TransIT LT1 (Mirus Corporation) and plasmids in 
the ratio 0.25 g pSTrRVFV-SNNSs:hRLuc: 0.50 g pN: 0.75 g pRdRp.  At 48 h 












Figure 3.1.  RecN binds non-specifically to E. coli RNA. 
(A) RecN was purified under native conditions with extensive RNase A treatment, and eluted from the size-
exclusion column predominantly as an oligomer (apparent molecular weight of 99 kDa) with a small 
fraction of monomer.  The RNA was extracted from recN oligomer and recN monomer then treated with 
RNase or DNase. The purified RNA was separated on a denaturing urea-polyacrylamide gel and visualized 
using SYBR Green. (B) Increasing amounts of RNA purified as in (A) from 80 μg of the recN oligomer 
were separated on a denaturing urea-polyacrylamide gel and visualized using SYBR Green.  The amounts 
loaded correspond to 2.5, 5.0, 10, 20, and 40% of total RNA purified.  Dominant RNA species are indicated 








Figure 3.2. RVFV N purification under denaturing conditions. 
 (A) S75 gel filtration chromatogram of refolded RVFV N. The red and blue traces represent absorption at 
260 nm and 280 nm, respectively. Peak A is in the void volume, peak B is the N dimer and peak C is the N 
monomer. Even after denaturation, some N is still bound to RNA and elutes as an oligomer. (B) SDS-
PAGE of fractions from the chromatogram shown in (A). Lane 1: molecular weight markers, lane 2: input 
sample, lane3: peak A fraction, lane 4: peak B fraction, and lanes 5-10: peak C fractions. (Contributed by 






Figure 3.3. Similar multimer complexes of authentic virus RNPs and purified recombinant N bound to 
RNA. 
 (A) Viral RNP. Purified RVFV RNPs were cross-linked with 0.0, 5.0, or 20.0 mM DSP and analyzed by 
immuno-blot. Asterisks indicate predominant cross-linked species. Molecular weight markers are in the 
rightmost lane. (B) Recombinant N. N or N bound to U25 ssRNA (N-RNA) was cross-linked using 0.0, 
1.0, 5.0, 10.0, or 20.0 mM DSP, separated by SDS-PAGE, and visualized with colloidal Coomassie stain. 
The dominant cross-linked species are indicated by asterisks (*). (Contributed by M. Piper) 
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Table 3.1. Diffraction data and Refinement Statistics 






Figure 3.4. Structure of RVFV N monomer 
(A) Polypeptide fold. The stereo ribbon diagram is colored as a rainbow from blue at the N terminus to red 
at the C terminus with loops in grey. Helix α7, (horizontal) in the center of the image, links the N-lobe at 
the bottom and the C-lobe at the top. (B) Diagram of helical secondary structure in the RVFN polypeptide. 




Figure 3.5. Electron density of RVFV N at the N and C-termini.  
(A) 2Fo-Fc map of the N-terminal helix contoured at 1σ. Residues 1-12 are shown in sticks. (B) 2Fo-Fc map 
of residues 241-245 at the C-termi- nus. Residues Arg178 and Lys189 are also depicted along with the salt 






Figure 3.6. RVFV N dimer. 
(A) Front view along the dimer axis. Monomers are in green and cyan and the molecular twofold is 
indicated by an ellipse. (B) Details of the dimer interface. The chains are colored as in (A), side chains with 
dimer contacts are shown in stick form in the stereo view. Hydrogen bonds are shown as dashed lines. 







Figure 3.7. Sequence alignment of N from the phlebovirus genus. 
Invariant residues are show in white with red background, consensus residues are shown in red with white 
background, and variable residues are show in black with white background. The observed α and η (310) 
helices are indicated above the alignment. Accession numbers are listed in Table S3. The sequence 
alignment was generated by clust- alW2 and the secondary structure annotations were assigned using 





Table 3.2.  Phlebovirus N catagorized by serocomplex.  
Phlebovirus N catagorized by serocomplex. The virus names, strains, accession numbers, and lengths of N 




Figure 3.8.  Conservation and atomic mobility in the RVFV N dimer. 
(A) Sequence conservation. Front and side views of the N dimer with chain A and B colored green and 
cyan, respectively. The residues that are invariant among phleboviruses N (brown) are located primarily in 
the core of the protein. (B) Atomic mobility. Side view of the N dimer is colored as a rainbow according to 







Table 3.3. Formation of dimer and C-terminal salt bridge are required for N function. 
Wild type (WT), W125A, R178Q, and R178E N alleles were analyzed for function by the transcription 
assay described in the Material and Methods. Renilla luciferase (RLU) activity was measured at 48 h post-
infection and is expressed relative to the no-N control and as a percent of WT activity. Data are the average 






Figure 3.9. Protein levels and multimer formation for N mutant and wild type alleles. 
The same cells used for the RdRp transcription assay (Table 3.2) were also analyzed for protein expression 
and N complex formation. Extracts were cross-linked using 0.0, 5.0 or 20.0 μM DSP. Protein complexes 
were then separated by SDS-PAGE and visualized by immunoblot. The dominant cross-linked species are 





Figure 3.10. Properties of the RVFV N surface. 
(A) Electrostatic surface potential. The surface potential from –20 kT in red to +20 kT in blue is shown for 
the front, side, back, and top of the RVFV N dimer. The front view is along the dimer axis as in (3A). (B) 
Sequence conservation. The surface of the RVFV N dimer is colored by conservation among phleboviruses 




Figure 3.11.  Homology models of N dimers from representative phleboviruses. 
Electrostatic potential surface is shown for of the front (left), side, back and top (right) of phlebovirus N 
dimers from (A) RVFV (ZH-501) crystal structure, (B) Naples (ELB), (C) Punta Toro (Adames), (D) 
Icoaraci (BeAn356637), and (E) Uukuniemi (Uukuniemi). Surface potential is shown by color from -20 kT 
in red to +20 kT in blue.  (Contributed by D. Raymond) 
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Chapter 4  
 
Encapsidated Genome Triggers Cellular Release of the Rift Valley Fever Virus 
 
Introduction 
Rift Valley fever virus (RVFV) is an aerosol- and mosquito-borne virus endemic 
to sub-Saharan Africa (40).  RVFV causes periodic, explosive epizootics, affecting 
livestock and humans (40).  Sheep and cattle are particularly susceptible to the virus, with 
abortion rates approaching 100% and high mortality rates among young animals (30).  By 
contrast, most humans infected with RVFV have a flu-like illness (40).  However, a small 
percentage of cases are more severe and include manifestations such as, hemorrhagic 
disease and encephalitis (29, 32, 120).  Despite the severity of the disease to the economy 
and human health, there are no USDA or FDA-approved therapeutic or prophylactic 
treatments. A better understanding of the RVFV replication cycle may lead to the 
identification of novel therapeutic targets. In this study, we have identified roles for each 
of the viral structural components in the assembly and release of the RVFV and have 
identified a potential conserved target for therapeutic development. 
RVFV is a segmented, negative-sense RNA virus belonging to the family 
Bunyaviridae, genus Phlebovirus.  The 12 kilobase genome is comprised of three 
segments termed L, M and S, which encode for the RNA-dependent RNA polymerase 
(RdRp), envelope glycoproteins (Gn/Gc) and nucleocapsid protein (N), respectively (40).  
The S and M segments also encode nonstructural proteins known as NSs and NSm, 
however these proteins are dispensable for RVFV replication in cell culture (40, 47, 48, 
54, 121).  Upon entry into host cells, the encapsidated genome and RdRp are released 
into the cytoplasm where transcription and replication of the viral genome occurs (122).  
The RdRp acts as both transcriptase and replicase (85), but requires N for both activities 
(57).  RdRp and N do not contain signal peptides, and presumably translation of the 
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RdRp and N occurs in the cytoplasm.  The glycoproteins enter the secretory pathway as a 
precursor polyprotein, which is cleaved by signal peptidase into the mature Gn and Gc 
proteins (49).  Gn and Gc form a complex and localize to the Golgi apparatus, the site of 
virus assembly, due to a localization signal on Gn (49, 58, 123).  It is not known how the 
encapsidated genome and RdRp are recruited to the Golgi apparatus for virus assembly or 
which viral components are involved in the cellular release of virus. 
Utilizing a Rift Valley fever virus-like particle (RVF-VLP) system, we have 
determined that the encapsidated genome acts as the primary stimulus for RVFV release 
from the cell, illustrating a novel, elegant mechanism for the efficient release of 
infectious particles.  We demonstrate that Gn is necessary and sufficient for packaging of 
the RdRp and encapsidated genome. Furthermore, we show that distinct and non-
overlapping regions of the Gn cytosolic tail are responsible for binding to RdRp and 
encapsidated genome. 
Results 
RVFV and RVF-VLPs have similar morphology and protein content.  
A T7 RNA polymerase-dependent system was used for the efficient generation of 
RVF-VLPs (Chapter 2).  Briefly, RVF-VLPs were produced by expression of an S 
segment-based minigenome (pSTrRVFV-SNNSs::hRLuc), N, RdRp, Gn, and Gc in 
BSR-T7/5 cells.  The minigenome contains a humanized renilla luciferase (RLuc) gene in 
place of the NSs ORF, and an internal deletion in the N gene that prevents expression of 
N.  RVFV and RVF-VLPs were harvested by ultracentrifugation and analyzed for 
particle morphology by transmission electron microscopy (Fig. 4.1A) or for protein 
composition by immunoblot (Fig. 4.1B).  RVFV and the RVF-VLPs exhibited similar 
morphology by transmission electron microscopy, although the RVF-VLPs were slightly 
larger than RVFV.  The difference in size may reflect the fact that RVF-VLPs package 
only the S segment-based minigenome, while RVFV packages all viral genomic 
segments.  RVFV has been shown to package multiple copies of a single genomic 
segment, and it is possible that the RVF-VLPs may package more S segments than the 
total number of segments packaged by RVFV.   
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All of the viral proteins were detected in the cell lysates (C) and within the 
harvested particles (P) in similar relative levels for RVFV and the RVF-VLPs (Fig. 
4.1B).  In addition to similarities in particle morphology and protein composition, RVFV 
and the RVF-VLPs are antigenically indistinguishable and respond similarly to inhibitor 
compounds (Chapter 2).  All of our data suggest the RVF-VLPs function similar to virus 
and will be useful in dissecting steps of the RVFV replication cycle.  
Gn is sufficient for recruitment of the RdRp to the Golgi apparatus for assembly.   
Replication and transcription of the viral genome by the RdRp occurs in the 
cytoplasm, while the assembly of virus particles takes place at the Golgi apparatus (40).  
We investigated the localization of the RdRp in the absence of other viral proteins. While 
it is believed that the RdRp of bunyaviruses are translated on free ribosomes in the 
cytoplasm (122), the localization of wild-type RVFV RdRp has not been investigated 
previously.  When expressed in the absence of other viral proteins, the RVFV RdRp was 
found distributed diffusely throughout the cytoplasm (Fig. 4.2A). The RdRp did not co-
localize with the resident Golgi protein, GS-28 (Fig. 4.2A).  By contrast, the envelope 
glycoprotein, Gn, co-localized with -COP, another resident Golgi protein in agreement 
with previously published reports (Fig. 4.2A) (123) . The C-terminal cytoplasmic tails of 
the envelope glycoproteins are presumably available for interaction with the RdRp.  To 
determine whether the glycoproteins are capable of targeting the RdRp to the Golgi 
apparatus, the RdRp was expressed together with Gn and Gc.  RVFV Gn and Gc are both 
integral membrane proteins that are expressed as a polyprotein that enters the secretory 
system (124).  The polyprotein is cleaved by signal peptidase, generating the mature Gn 
and Gc proteins (49), and it is believed that the mature Gn glycoprotein retains the signal 
peptide of Gc (49, 125). Expression of the glycoproteins along with the RdRp resulted in 
localization of RdRp to a focus of intense staining co-localizing with the Gn and Gc 
complex at the Golgi apparatus (Fig. 4.2B), indicating that one or both of the 
glycoproteins are necessary for recruitment of RdRp to the Golgi for virus assembly.  
When Gc was expressed alone with the RdRp, the cytoplasmic localization of the RdRp 
was not altered (Fig. 4.2B). By contrast, co-expression of Gn with the RdRp was 
sufficient to target the RdRp to the site of assembly (Fig. 4.2B).  Therefore, Gn is 
necessary and sufficient for the recruitment of RdRp to the Golgi apparatus.   
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To identify the domain of Gn that interacts with RdRp, a mutant Gn allele that 
lacks the last 40 amino acids of the cytoplasmic tail and the Gc signal peptide (GnK48) 
was investigated for its ability to interact with the RdRp.  Although the GnK48 mutant 
localizes properly to the Golgi apparatus (123) and is capable of forming a complex with 
Gc (data not shown), it was unable to recruit the RdRp to the Golgi apparatus (Fig. 4.2B).  
Therefore, the last 40 amino acids of the Gn cytoplasmic tail and/or the Gc signal peptide 
is necessary for the recruitment of the RdRp to the Golgi apparatus.  
Generation of infectious RVF-VLPs requires packaging of a catalytically active RdRp. 
To investigate whether assembly of the RdRp at the Golgi apparatus corresponded 
to packaging of the RdRp into particles, we investigated the protein profiles of the RVF-
VLPs containing all viral components (WT), lacking the RdRp (-RdRp), or containing the 
GnK48 allele (GnK48).  BSR-T7/5 cells were transfected with minigenome, pN, pRdRp, 
pGn, and pGc or one or more of the components were replaced with an equivalent 
amount of empty vector or pGnK48. RVF-VLPs were visualized by transmission electron 
microscopy and protein composition was determined by immunoblot.  Particles were 
generated for all conditions and there were no gross differences in size or morphology 
(Fig. 4.3A), indicating the RdRp is not required for generation of particles.  As expected, 
no RdRp signal was observed with RVF-VLPs that lacked RdRp (-RdRp) or contained 
GnK48, but RdRp was present when all components were expressed (WT) (Fig. 4.3B).  
Next, we determined whether a catalytically active RdRp is required for interaction with 





for recruitment by Gn to the Golgi apparatus.  Using immunofluorescence microscopy, 




, indicating that RdRp 
catalytic activity is not required for interaction with Gn (Fig. 4.3C).  These results are 
supported by our immunoblot results showing that RdRp
cat1
 is packaged into RVF-VLPs 
(Fig. 4.3B).  Finally, we investigated whether catalytically active RdRp co-expressed 
with N in target cells (trans expression) could rescue infectivity of RdRp-deficient or 
RdRp
cat1
 RVF-VLPs.  Wild-type RVF-VLPs were capable of infecting untransfected 
target cells and expressing the RLuc reporter at levels 700-fold above background (Table 
4.1).  Transcription of the RLuc reporter in target cells could be enhanced through 
expression of a catalytically active RdRp with N in trans, increasing RLuc signal to 
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4,000-fold background levels (Table 4.1).  Expression of a catalytically inactive RdRp 
mutant with N in target cells did not enhance RLuc signal as compared to untransfected 
target cells (Table 4.1).  These results indicate the catalytically active RdRp expressed in 
trans could access the encapsidated genome delivered by the wild-type RVF-VLPs for 
enhancement of RLuc expression (Table 4.1).  However, RVF-VLPs packaging RdRp
cat1
 
or RVF-VLPs lacking the RdRp (-RdRp) could not be complemented in trans with an 
active RdRp (Table 4.1).  Wild-type RVF-VLPs were the only RVF-VLPs to generate a 
significant RLuc signal as compared to background (-Gn/-Gc) (Table 4.1).  Therefore, 
virion-derived, catalytically active RdRp must be present in order for replication to begin 
in a target cell.   
Encapsidated genome is packaged into virions by Gn.  
After transcription and replication of the viral genome in the cytoplasm, we 
hypothesized that encapsidated genome and RdRp were recruited as a complex to the 
Golgi apparatus for assembly through interaction between the RdRp and Gn.  However, 
we discovered that the encapsidated genome could be packaged into RVF-VLPs lacking 
the RdRp (Fig. 4.3B, -RdRp and GnK48).  Therefore, the encapsidated genome and the 
RdRp can be packaged independently. Phlebovirus N localizes to the cytoplasm when 
expressed alone (data not shown), similar to N of tomato spotted wilt virus  (Tospovirus 
genus) (127) and La Crosse virus (Orthobunyavirus genus) (128), but in contrast to 
Hantaan and Black Creek Canal viruses N (Hantavirus genus) (129, 130).  Therefore, N 
from phleboviruses presumably interact with one or both of the envelope glycoproteins in 
order to be assembled into virions.  The GnK48 allele was able to package RVFV N (Fig. 
4.3B), which indicates that the last 40 amino acids of the 70 amino acid Gn cytoplasmic 
tail and the Gc signal peptide are not required for packaging of N.  Accordingly, Gc 
and/or the first 30 amino acids of the Gn cytoplasmic tail appear necessary for its 
packaging.  To determine whether Gn or Gc is involved in N packaging, we transfected 
cells with all viral components or equivalent amounts of plasmid encoding the GcW1 
allele or empty vector.  GcW1 has a premature stop codon at Trp1189, which deletes the 
predicted Gc cytoplasmic domain in its entirety. Particles lacking Gn or Gc, or containing 
GcW1, were analyzed for morphology and protein content (Fig. 4.4A and B).  All 
conditions produced RVF-VLPs as determined by transmission electron microscopy (Fig. 
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4.4A), except no particles could be found when either both glycoproteins or N were 
omitted.  RVF-VLPs lacking either Gn or Gc were smaller than wild-type RVF-VLPs 
(Fig. 4.4A), possibly due to differences in the packing of glycoproteins in the envelope.  
The level of glycoproteins expressed in the transfected cells varied by experimental 
condition (Fig. 4.4B).  Co-expression of full-length Gn and Gc was required for high-
level expression of each glycoprotein.  Previous studies with the Bunyamwera virus 
(Bunyaviridae family) identified a chaperone-like role of Gn in the folding of Gc, and the 
requirement of the Gc ectodomain, which extends into the ER/ Golgi lumen, for efficient 
Golgi trafficking of Gn (131, 132). Therefore, these results were not surprising.  The 
average glycoprotein signal within RVF-VLPs generated with Gn or Gc alone was near 
background levels (Fig 4.4B).  Interestingly, N was still packaged into RVF-VLPs that 
lack Gc (Fig. 4.4B).   By contrast, no N was found in RVF-VLPs that lacked Gn (Fig. 
4.4B), demonstrating that Gn is necessary and sufficient for packaging of N, presumably 
in the form of encapsidated genome.  When Gn was expressed with GcW1, both N and 
the RdRp were packaged into RVF-VLPs, supporting the view that Gn alone recruits both 
encapsidated genome and RdRp (Fig 4.4B).  Consistent with the immunoblot results (Fig. 
4.4B), the GcW1 RVF-VLPs were infectious and yielded RLuc signals significantly 
above background levels in target cells complemented in trans with active RdRp and N 
(Table 4.2).  Based on these data we can conclude that Gn is capable of packaging the 
encapsidated genome in the absence of Gc.  However, generation of infectious particles 
requires co-expression of the ecto- and transmembrane domains of Gc.  
Encapsidated genome triggers cellular release of virus.  
Gn can package both the RdRp and encapsidated genome independently into 
RVF-VLPs.  Therefore, we investigated the individual roles of each of these viral 
components in the release of RVF-VLPs from cells.  To determine the minimal viral 
components necessary for the efficient cellular release of RVF-VLPs, cells were 
transfected with minigenome, pN, pRdRp, pGn, and pGc, or one or more of the 
constructs were replaced by an equivalent amount of empty vector.  The RVF-VLPs were 
visualized by transmission electron microscopy, analyzed for protein content by 
immunoblot, and examined for infectivity by RLuc expression in target cells.  RVF-VLPs 
were visualized by transmission electron microscopy for all conditions; however, no 
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particles could be found when both envelope glycoproteins or N were absent (data not 
shown).  The RVF-VLPs did not differ morphologically from RVFV (Fig. 4.1).  When 
wild-type viral proteins and genome were expressed, RVF-VLPs were released from the 
cell and all viral proteins could be visualized (Fig. 4.1).  No particles were visualized by 
electron microscopy when the genome, N, and RdRp, which form the viral 
ribonucleoprotein complex, were expressed without the envelope glycoproteins (-Gn/-
Gc) (data not shown) and there was no expression of the RLuc reporter above 
background levels in target cells (Table 4.3).  Our results corroborate the results of 
previous findings that ribonucleoprotein complexes are not released from the cell in the 
absence of glycoproteins (133).  Additionally, RVF-VLPs lacking N produced no RLuc 
signal above background, demonstrating that naked genome is not packaged and/or is not 
infectious (Table 4.3). 
To determine which viral components are necessary for efficient RVF-VLP 
release, we quantified RVF-VLP release efficiency for all experimental conditions.  For 
the purpose of this analysis we equated RVF-VLP release with Gn/Gc levels.  Gn/Gc 
expression levels from the immunoblots of the RVF-VLPs were measured and 
normalized to expression levels in transfected cells.  The experimental condition that 
included all structural proteins and genome (WT) was designated as 100% release 
efficiency, and the condition in which both envelope glycoproteins were omitted from the 
transfection (-Gn/Gc) was considered background  (Fig. 4.5B, Table 4.4).  The samples 
lacking N or the genome exhibited average release efficiencies of only 15.6 and 18.1%, 
respectively, compared to wild-type (Table 4.4). These efficiencies were similar to when 
the entire ribonucleoprotein complex was absent (Table 4.4, -RNPC). Our results 
demonstrate an absolute requirement for both N and the genome, presumably in the form 
of encapsidated genome, for efficient virus release.  Conversely, the absence of RdRp did 
not significantly affect the efficiency of release of the glycoproteins (Fig. 4.5B and Table 
4.4), indicating that RdRp does not play a critical role in viral budding or release.  In all 
individual experiments, we detected increased release efficiency for RdRp-deficient 
RVF-VLPs, with average release efficiency corresponding to 169.5% of wild-type RVF-
VLPs, although the increase was not statistically significant (Table 4.4).  While particles 
can be generated at low levels lacking either Gn or Gc (Fig. 4.4A), the amount of Gn or 
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Gc in RVF-VLPs was at or below the limit of detection by immunoblot; therefore, release 
efficiencies could not be calculated.  The RVF-VLPs lacking the cytoplasmic portions of 
Gn or Gc exhibited decreased release efficiencies in all individual experiments, but only 
for Gn was this significant (Table 4.4). The encapsidated genome is packaged in both 
conditions (Fig. 4.3B and 4.4B); therefore, the glycoprotein cytoplasmic tails likely 
perform additional functions in the release process.  These results indicate that genome 
and N, presumably in the form of encapsidated genome, are required but RdRp is 
dispensable for efficient RVF-VLP release.   
Discussion 
 The encapsidated genome of RVFV acts as a trigger for the cellular release of 
virus.  Viral genomes have not been implicated in stimulating the budding and/or release 
of any negative or positive-sense RNA virus prior to this report.  Our results suggest a 
model for RVFV assembly and release that is diagrammed in Figure 4.6.  The envelope 
glycoproteins enter the secretory system as a polyprotein and are then cleaved by signal 
peptidase to yield mature Gn and Gc (49).  Gn and Gc form a heteromeric complex in the 
endoplasmic reticulum and localize in steady-state to the Golgi apparatus by virtue of a 
signal found on Gn (Fig. 4.6, #1) (123).  The cytoplasmic RdRp and encapsidated 
genome are recruited to the site of assembly through independent interactions with Gn 
(Fig. 4.6, #2).  Multiple interactions between the encapsidated genomic segments and Gn 
proteins induce membrane curvature and trigger the budding of viral particles into the 
lumen of the Golgi apparatus (Fig. 4.6, #3), followed by release of virus from the cell 
(Fig. 4.6, #4).   
With the encapsidated genome acting as the stimulus for budding, nearly all 
RVFV particles should contain genome. Thus, it is a reasonable expectation that most 
particles should be infectious.  While most enveloped, RNA viruses typically yield 
particle-to-plaque-forming unit (pfu) ratios in the tens or hundreds (134-137), studies 
with Bunyamwera virus (Orthobunyavirus genus) determined that the particle-to-pfu 
ratio approaches one (138). We propose that efficient generation of infectious particles is 
achieved through the encapsidated genome promoting the cellular release of virus.  The 
L, M, and S segments are proposed to be packaged at a molar ratio of approximately 
1:4:4 in RVFV particles (1 L segment, 4 M segments, 4 S segments) (41).  Therefore, we 
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hypothesize that there is a minimum amount of encapsidated genome (~28 kilobases) 
necessary to induce sufficient membrane curvature at the Golgi apparatus; however, we 
have no data to support or contradict this hypothesis.  We propose the interactions 
between the encapsidated genomic segments and multiple Gn proteins results in 
accumulation of the glycoproteins and ribonucleoprotein complexes at specific areas of 
the Golgi apparatus, causing a change in membrane curvature and virus particle budding 
into the Golgi lumen.  The virus buds when the critical quantity of genome is bound. 
Our results support studies performed by Liu et. al. using a baculovirus expression 
system for generation of RVF-VLPs in insect cells.  Liu et. al. found that particles could 
be generated through expression of Gn and/or Gc with N.  Similarly, we could not 
identify any particles by electron microscopy unless N and Gn or Gc were expressed.  
Based on their ability to visualize particles, Liu et. al. concluded that only N and the 
envelope glycoproteins were required for efficient generation of particles (73).  Liu et. al. 
did not calculate release efficiency of RVF-VLPs, so the viral components required for 
efficient release could not be determined.  Similar to Liu et. al., we observed particles 
that lacked genome using EM (Fig. 4.5); however, our quantitative analysis indicates that 
genome, in addition to N, is absolutely required for the efficient cellular release of virus 
(Table 4.4).  
Most RNA viruses require a matrix protein for the packaging of the 
ribonucleoprotein complexes and release of viral particles (40, 139-152), however viruses 
of the Bunyaviridae family do not encode a matrix protein.  Based on our results, the Gn 
cytoplasmic tail appears to function in place of matrix and interacts directly with the 
ribonucleoprotein complexes and RdRp. We identified Gn as being necessary and 
sufficient for the assembly and packaging of the RdRp and the encapsidated genome into 
particles. RdRp could be recruited to the Golgi apparatus and packaged into virions by 
full-length Gn.  However, the RdRp could not be packaged by a Gn allele (GnK48) that 
lacked the last 40 amino acids of the cytoplasmic tail and the Gc signal peptide, although 
particles were formed.  These results suggest that the interaction domain of Gn with the 
RdRp contains the C-terminal half of the Gn cytoplasmic tail, since the Gc signal peptide 
likely remains in the membrane and thus could not interact with cytoplasmic RdRp.  By 
contrast, N, presumably bound to genome, could be packaged into virions by the 
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truncated Gn allele (GnK48).  This result indicates that the interaction domain of Gn with 
the encapsidated genome is located within the first 30 amino acids of the cytoplasmic tail.  
Thus, different regions of the Gn cytoplasmic tail are required for independent 
interactions with RdRp and the encapsidated genome.  The Gn interaction domain for the 
encapsidated genome corresponds to a region that is highly hydrophobic in RVFV Gn.  
The hydrophobic character of this domain is conserved amongst phleboviruses (123) and 
could function in protein-protein interactions with N.  In concert with our study, 
Raymond et. al. (Chapter 3) have crystallized the RVFV N and discovered a hydrophobic 
pocket that is highly conserved amongst phlebovirus N.  This hydrophobic pocket is 
dynamic and likely to be involved in protein-protein interactions (Chapter 3).  We 
hypothesize that the hydrophobic pocket of N interacts with the hydrophobic residues of 
the Gn cytoplasmic tail for the packaging of the encapsidated genome and for triggering 
virus release.  Studies performed with the Uukuniemi virus (Phlebovirus genus) similarly 
found that the Gn cytoplasmic tail to be required for the packaging of N, but identified a 
different region to be important for this interaction (86).  However, the envelope 
glycoproteins and N of Uukuniemi virus are divergent from the rest of the phlebovirus 
genus, which may explain why our results contrast. Gn interaction with N is unlikely to 
be conserved across the five genera within family Bunyaviridae, as the envelope 
glycoproteins and N are not similar. The N (and RdRp) of the hantaviruses independently 
localize to perinuclear membrane structures when expressed alone, suggesting a distinct 
mode of assembly (129, 153).  For tospoviruses, independent interactions between Gn 
and Gc with N were discovered, indicating a possible requirement for both glycoproteins 
during recruitment (127).   
We found no role for Gc in recruitment of encapsidated genome or RdRp, 
however, Gc is necessary for optimal Gn expression, as well as minigenome expression 
in RVF-VLP-infected target cells. These results suggest that Gc plays a role in entry, 
perhaps through recognition of cell surface receptors and/or fusion.  Studies performed 
by Bellesar and Blackburn (154) suggest a requirement for Gc in virus entry, as they were 
able to neutralize virus using antibodies recognizing either Gn or Gc, either pre- or post- 
virus absorption.   These results indicate that both glycoproteins play a role in entry into 
target cells.  Computational studies have predicted RVFV Gc to be a class II viral fusion 
78 
protein (155), and previous experiments with other viruses of the Bunyaviridae family 
support Gc being the main determinant of cell fusion (156-158).  Fusion assays utilizing 
Gn and Gc of Bunyamwera virus (Orthobunyavirus genus, Bunyaviridae family) found 
that deletions in Gc prevented syncitia formation (158).  Additional experiments with La 
Crosse and Tahyna viruses (Orthobunyavirus genus) identified Gc as fusion protein using 
chimeras, site-directed mutagenesis, and cell-cell-fusion assays (156, 157).  
Although it has been widely acknowledged that the RdRp is fundamental to 
replication and transcription of the RNA virus genome, other roles for the RVFV RdRp 
have not been previously explored.  We have discovered that while the RdRp was not 
required for the efficient cellular release of virus or packaging of the encapsidated 
genome, a catalytically active RdRp must be packaged for RdRp expressed in trans to 
transcribe the genome.  Complementing in trans with viral components required for 
transcription/replication is not unprecedented.  Studies with the Ebola virus (Ebolavirus 
genus, Filoviridae family), which is a non-segmented negative-sense RNA virus, 
investigated the viral components necessary for the generation of infectious particles. The 
Ebola virus VP30 protein, which is required for replication/transcription by the RdRp, 
could be complemented in trans for restoration of activity in Ebola-VLP-infected target 
cells (159).  For RVFV, it is necessary that the genome, N, and the RdRp be packaged, 
and the RdRp appears to be essential for an early step in the RVFV replication cycle.  
While the RdRp may play a role in entrance into target cells, it is more likely that the 
encapsidated genome is initially not accessible to the RdRp expressed in trans. We 
hypothesize that catalytically active RdRp must be bound to the genome for the initial 
round of replication and/or transcription.   
Previous studies with the positive-sense RNA viruses, poliovirus (Picornaviridae 
family) and Flock house virus (Nodaviridae family) found that only actively replicating 
genomes were recruited for virus assembly (160-162).  For poliovirus, it is hypothesized 
that translation is coupled to replication of the genome and assembly of the virus, so that 
only genomes that encode functional proteins are replicated and packaged (160).  For the 
Flock house virus, it is hypothesized that the replicating and non-replicating RNA 
genomes segregate to distinct sub-cellular locations, allowing for packaging of only the 
replicating RNA (162).  In contrast to poliovirus and Flock house virus, RVFV can 
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package replicating or non-replicating ribonucleoprotein complexes (as measured by 
packaging of N and RdRp).   However, only catalytically active complexes can be 
significantly enhanced through the expression of RdRp and N in trans.  Perhaps the 
concentration of genome is too low in cells that are replication-defective to be enhanced 
by expression of RdRp and N in trans.  Alternatively, catalytically active RdRp may need 
to be bound to the encapsidated genome for an early event in the replicative cycle.  
We have illuminated roles for each of the viral components in the assembly, 
cellular release, and infectivity of RVFV. The interaction between the encapsidated 
genome and the Gn cytoplasmic tail triggers release of virus, likely through stimulating 
budding of the virus into the Golgi, illustrating a novel mechanism for the efficient 
generation of infectious virus particles.  The design and screening of therapeutics 
targeting the Gn cytoplasmic tail may offer a novel target for inhibition of both virus 
release and packaging of the RdRp and encapsidated genome.  
Materials and Methods 
Plasmid Constructs 
All plasmids were generated using standard molecular cloning techniques and 
were confirmed by sequencing.  The constructs pTrRVFV-SNSs::GFP, pN-Amp, 
pRdRp-Amp, pGn/Gc-Amp, and pGnK48Stop-Amp have been described previously (54, 
123).  The minigenome, pSTrRVFV-SNNSs::hRLuc, was derived from pTrRVFV-
SNSs::GFP by replacing the GFP gene with a humanized renilla luciferase gene (RLuc), 
then deleting a 237 nucleotide Sma I fragment of the N gene.  The expression constructs 
for N and RdRp were generated through cloning the open reading frames into pVAX1 
(Invitrogen) using the HindIII/EcoRI and BamHI/NotI sites, respectively.   The open 
reading frames from pGn/Gc-Amp and pGnK48Stop-Amp were cloned into pVAX1 
using BamHI and EcoRI sites, generating pGn/Gc, pGc, pGn, and pGnK48.  The 
expression plasmid, pGcW1, was generated by site-directed mutagenesis of Trp1189 to a 
stop codon in pGc, thus deleting the entire predicted cytoplasmic tail.  Site-directed 





, which were mutated to Ala at residues Asp1134 and Ser1132, respectively.  
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Cells and virus 
BSR-T7/5 cells were a generous gift of Dr. K. Conzelmann (Max-von 
Pettenkofer-Institut, Munchen, Germany).  The BSR-T7/5 clonal cell line was generated 
through limiting dilution of the BSR-T7 cells. The cells were grown in Dulbecco’s 
Modified Eagle Medium (Invitrogen) supplemented with 10% fetal calf serum, and 1 
mg/mL Geneticin.  RVFV ZH548 MP12 vaccine strain was a generous gift of Dr. R. 
Tesh (World Reference Center of Emerging Viruses and Arboviruses).   
Antibodies 
Hybridomas that secrete neutralizing monoclonal antibodies recognizing Gn and 
Gc (R1-4D4-1-1 and R5-3G2-1A) were a generous gift of Dr. G. Ludwig (USAMRIID).   
Polyclonal antibodies that were generated against RVFV in mice were a generous gift of 
Dr. P. Rollin (CDC). The N-terminal 150 amino acids of the RdRp and full-length N 
were expressed with N-terminal histidine tags and purified under denaturing conditions 
on Ni-NTA agarose columns (Qiagen Inc.). RdRp and N polyclonal antibodies were 
generated in rabbits using these purified proteins as antigens (Harlan Laboratories). 
Monoclonal antibodies recognizing GS-28 and -COP were purchased from 
Transduction Labs and ABR, respectively.  Horseradish peroxidase-conjugated secondary 
antibodies, goat anti-rabbit and goat anti-mouse, were acquired from Amersham and MP 
Biomedical, respectively.  AlexaFluor 488-labelled goat anti-rabbit and AlexaFluor 594-
labelled goat anti-mouse were purchased from Invitrogen. 
Virus-like particle production 
BSR-T7/5 cells were plated at a density of 1.2 x10
6
 cells/plate.  After 24 h, cells 
were transfected using 2 L TransIT LT1 (Mirus Corporation) /g DNA and plasmids in 
the ratio 6.0 g minigenome: 6.0 g pN: 6.0 g pRdRp: 3.0 g pGn: 3.0 g pGc/10 cm 
plate.  The amount of plasmid transfected was scaled to the number of cells. The media 
was changed 24 h post-transfection.  After 48 h post-transfection, the RVF-VLPs were 
harvested, then clarified by low-speed centrifugation (300 rcf for 10 min at 4˚C) to 
remove cellular debris.  The transfected cells were analyzed by RLuc assay (Promega) as 
a means to determine transfection efficiency.  Only experiments exhibiting high 
transfection efficiencies were further analyzed for RVF-VLP production.  The RVF-
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VLPs were purified by high-speed ultracentrifugation for visualization by electron 
microscopy, immunoprecipitated for analysis by immuno-blot, or diluted for infection of 
target cells.  RVF-VLP-infected target cells were harvested 24 h post-infection and were 
analyzed for RLuc activity.  The raw luciferase units (RLU)/mL of RVF-VLPs added to 
target cells was calculated for three or more separate experiments.  The log of the average 
RLU/mL was calculated for analysis by Independent T-Test (SPSS Statistical Package 
14.0), and compared to the negative control (-Gn/-Gc).  The p-values were calculated for 
an -value of 0.05. 
Immunoprecipitation of RVF-VLPs 
Mouse monoclonal antibodies recognizing either Gn (R1-4D4-1-1) or Gc (R5-
3G2-1A) were conjugated to Dynal magnetic beads (Invitrogen) by incubating overnight 
at ˚C.  The antibody-coated beads were incubated overnight at ˚C with RVFV or RVF-
VLPs, then washed with Wash buffer (10mM Tris, 5mM MgCl2, and 100mM NaCl, pH 
7.8), and resuspended in 1X sample buffer for analysis by immuno-blot.  To prevent 
variation between conditions, generation of RVF-VLPs, immunoprecipitation, and 
immunoblotting were performed for all conditions at the same time.  The representative 
immunoblots in the figures are from a single immunoblot split into the different figures.  
Therefore, each figure displays the same positive (WT) and negative (-Gn/-Gc) controls 
for comparison. The extensive experiments were performed multiple times, but only an 
immunoblot from a single experiment is shown. 
Transmission electron microscopy 
RVFV and RVF-VLPs were pelleted by high-speed ultracentrifugation (82,705 
rcf for 4 h at 4˚C), resuspended in 0.1M Sorenson’s buffer, and distributed onto a carbon-
coated grid.  The particles were fixed with 2.5 % glutaraldehyde in Sorensen's buffer and 
negative stained with aqueous 1% uranyl acetate, which was performed by the 
Microscopy Imaging Laboratory (University of Michigan).  The particles were viewed on 
a Philips CM100 transmission electron microscope at 60 KV.  Images were recorded 
digitally using a Hamamatsu ORCA-HR digital camera system, which was operated 
using AMT software (Advanced Microscopy Techniques Corp., Danvers, MA).  The 
sizes of RVFV and RVF-VLPs were measured for three or more particles. 
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Efficiency of RVF-VLP Cellular Release 
Efficiency of cellular release was determined through quantitation of Gn/Gc 
levels in the cell lysates and within the RVF-VLPs.  Immunoblots were analyzed using 
ImageQuant 5.2 (Molecular Dynamics) to determine the signal intensity (volume).  The 
Gn/Gc expression levels were normalized to Gn/Gc expression in transfected cells, and 
calculated as a percentage of the WT condition, which was designated as 100% release 
efficiency.  Statistics were performed for the comparison of Gn/Gc expression levels 
from experiments performed in triplicate using one-sample t-tests (SPSS Statistical 
Package 14.0).  The p-values were calculated for an -value of 0.05. 
Immunofluorescence 
BSR-T7/5 cells were plated on glass coverslips at 5.0 x 10
4
 cells/well of a 24-well 
plate.  After 24 h, the cells were transfected using 2 l TransIT/g DNA. The cells were 
fixed 24 h post-transfection with 4% paraformaldehyde in phosphate-buffered saline 
(PBS), then permeablilized using 0.2% Triton X-100 in PBS with 1% bovine serum 
albumin.  Mouse monoclonal antibodies recognizing Gn and Gc and rabbit polyclonal 
antibodies recognizing the RdRp and N were used as primary antibodies, while 
AlexaFluor488-labelled goat anti-rabbit and AlexaFluor 594-labelled goat anti-mouse 
were used as secondary antibodies (Invitrogen). Fluorescence visualization and imaging 
were performed using an Olympus 51-X fluorescent light microscope at the Microscopy 
Imaging Laboratory (University of Michigan). Cells with clear signals for both red 
(594) and green channels (488) were counted, then, analyzed for co-localization.  
Positive co-localization was defined as the RdRp exhibiting a focus of intense staining 
corresponding to the Golgi/glycoprotein signal.  Diffuse cytoplasmic staining and small 







Figure 4.1. RVFV and RVF-VLPs have similar morphology and protein composition. 
(A) RVFV and RVF-VLPs were harvested by ultracentrifugation and analyzed by transmission electron 
microscopy with negative staining. The particle sizes were measured, and the values listed are the mean 
sizes of particles with standard deviation. (B) BSR-T7/5 cells were transfected with pSTrRVFV-
SNNSs::hRLuc, pN, pRdRp, pGn, and pGc or were infected with RVFV ZH-548 MP12 vaccine strain at 
an MOI of 1.  The media, containing either RVF-VLPs or RVFV, was harvested, clarified, and the particles 
pelleted by ultracentrifugation.  Lysates from transfected or RVFV-infected cells (C), and pelleted particles 









Figure 4.2.  Gn recruits RdRp to the Golgi apparatus. 
(A) BSR-T7/5 cells were transfected with pRdRp or pGn, and the proteins were visualized with anti-RdRp 
and anti-Gn, respectively (green channel).  Cellular resident Golgi apparatus proteins, GS-28 or -COP 
were also labeled (red channel). Percentage of cells displaying co-localization of viral proteins with Golgi 
apparatus is indicated with the number of cells counted in parentheses.  (B) BSR-T7/5 cells were 
transfected with pRdRp and either pGn/pGc, pGc, pGn, or pGnK48.  Cells were incubated with anti-RdRp 
(green channel) and anti-Gn or anti-Gc (red channel), then analyzed by immunofluorescence microscopy. 
Percentage of cells displaying co-localization of RdRp with Gn or Gc is indicated with the number of cells 












Figure 4.3. Packaged, catalytically active RdRp is necessary for an early event in the RVFV replication 
cycle. 
(A) RVF-VLPs were harvested by ultracentrifugation and visualized by transmission electron microscopy 
with negative staining.  The particle sizes were measured, and the values listed are the mean sizes with 
standard deviation.  (B) BSR-T7/5 cells were transfected with plasmids expressing an artificial S segment 
and all of the structural proteins (pSTrRVFV-SNNSs::hRLuc, pN, pRdRp, pGn, and pGc), this 
condition is referred to as WT. Or, one or more of the components was replaced with an equivalent amount 
of empty vector (-Gn/Gc and –RdRp) or with plasmids expressing mutant alleles of Gn or RdRp (GnK48 or 
pRdRpcat1).  Transfected cells were analyzed for protein expression by immunoblot. RVF-VLPs were 
immunoprecipitated from the clarified media from transfected cells and analyzed by immunoblot. (C) BSR-
T7/5 cells were transfected with pGn and either pRdRp or RdRp catalytic domain mutants, pRdRpcat1 or 
pRdRpcat2.  Cells were incubated with anti-Gn (red channel) and anti-RdRp (green channel) then analyzed 
by immunofluorescence microscopy. Percentage of cells displaying co-localization of RdRp alleles with Gn 

















Figure 4.4. Gn packages encapsidated genome. 
(A) RVF-VLPs were harvested by ultracentrifugation and analyzed by transmission electron microscopy 
with negative staining.  The particle sizes were measured, and the values listed are the mean sizes of 
particles with standard deviation.  (B) BSR-T7/5 cells were transfected with plasmids expressing an 
artificial S segment and all of the structural proteins (pSTrRVFV-SNNSs::hRLuc, pN, pRdRp, pGn, and 
pGc), this condition is referred to as WT. Or, one or more of the components was replaced with an 
equivalent amount of empty vector (-Gn/-Gc, -Gn, or -Gc) or a plasmid expressing an allele of Gc that 
lacks the entire cytoplasmic tail (GcW1). Transfected cells were analyzed for protein expression by 
immunoblot. RVF-VLPs were immunoprecipitated from the clarified media from transfected cells and 





















Figure 4.5. Viral components required for efficient RVF-VLP release. 
(A) RVF-VLPs were harvested by ultracentrifugation and visualized by transmission electron microscopy 
with negative staining.  The particle sizes were measured, and the values listed are the mean with standard 
deviation. (B) BSR-T7/5 cells were transfected with plasmids expressing an artificial S segment and all of 
the structural proteins (pSTrRVFV-SNNSs::hRLuc, pN, pRdRp, pGn, and pGc), this condition is 
referred to as WT. Or, one or more of the components was replaced with an equivalent amount of empty 
vector (-RNPCs, -Gn/Gc, -N, -genome, -RdRp).  RNPCs refer to ribonucleoprotein complexes and are 
defined as genome, N, and RdRp.  Transfected cells were analyzed for protein expression by immunoblot. 







































Figure 4.6. Model for the assembly and budding of RVFV. 
Upon entry of RVFV into the cell, replication and transcription of the viral proteins occur in the cytoplasm.  
The RdRp and N are translated in the cytoplasm, while the envelope glycoproteins are translated as a 
polyprotein on the endoplasmic reticulum.  1) The polyprotein is cleaved into the individual Gn (green 
cylinders) and Gc (blue cylinders) proteins, which form a complex and localize to the Golgi apparatus by a 
localization signal on Gn.  2) The RdRp (starbursts) and N (yellow circles) form the ribonucleoprotein 
complex with the genome, and localize to the Golgi apparatus through independent interactions with the Gn 
cytoplasmic tail. 3) Interaction between the encapsidated genome and the glycoproteins induces negative 
membrane curvature and budding of virus particles into the lumen of the Golgi apparatus.  4) The 
disintegration of the Golgi apparatus leads to egress of the virus from the cell. 
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Chapter 5   
 
Limitations to Phlebovirus Reassortment 
Introduction 
Segmented, RNA viruses rapidly evolve to new geographical niches or hosts 
utilizing mechanisms of antigenic drift and antigenic shift.  Genetic drift involves the 
gradual accumulation of point mutations in the viral genome through replication by an 
error-prone RNA-dependent RNA polymerase (RdRp) (20).  Genetic shift leads to virus 
evolution through exchanging viral genomic segments with closely related viruses co-
infecting the same cell (20).  Genetic shift is referred to as reassortment and generates 
novel viruses that contain segments from each of the parental viruses.  The progeny virus 
may exhibit pathological features similar to either virus, or alternatively, may display a 
unique form of pathogenesis (20). 
In 2001, a reassorted virus from the Bunyaviridae family (Orthobunyavirus 
genus) emerged in East Africa. The virus contained genomic segments from the 
Bunyamwera (BUNV) and Batai (BATV) viruses (11, 17, 19).  While BUNV typically 
produces febrile disease in humans and BATV has not been implicated in human disease, 
the reassorted virus caused hemorrhagic fever disease in the human population, 
exhibiting a similar, yet more extreme pathological phenotype to BUNV (11).  The 
discovery of this virus, termed the Ngari virus, established the capacity of different 
viruses within the Bunyaviridae family to reassort in nature.  
The Rift Valley fever virus (RVFV) belongs to the Phlebovirus genus of the 
Bunyaviridae family.  RVFV is the causative agent of explosive epizootics throughout 
the African continent and the Arabian Peninsula, primarily targeting humans and 
livestock (163).  The mosquito vectors for RVFV can be found throughout the world (21-
24, 26-28, 51), and the capacity of RVFV to spread to previously unaffected regions has 
been demonstrated in Egypt in 1977 and in the Arabian Peninsula in 2000 (30).  There 
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are no FDA- or USDA-approved therapeutics or prophylactics available, and spread of 
the virus is detrimental to the regional economy and public health.  Upon introduction to 
a new region of the world, RVFV may be capable of reassorting with other viruses in the 
Phlebovirus genus (Bunyaviridae family), which are present throughout Eurasia and the 
Americas (40).  Understanding whether phleboviruses can reassort and the limitations 
governing reassortment, if any, will allow us to address or evade public health threats in 
the future. 
Similar to all phleboviruses, RVFV is a spherical, enveloped virus encoding four 
structural proteins on the S (small), M (medium), and L (large) genomic segments (40).  
The S segment encodes the nucleocapsid protein (N), while the M and L segments 
encode the envelope glycoproteins (Gn and Gc) and the RdRp, respectively (40). The 
RdRp acts as replicase and transcriptase (85), but requires N bound to the genome (57), 
as the encapsidated genome, for these processes to proceed.  Prior to release, the virus 
assembles at the Golgi apparatus (40).  Gn can recruit both the RdRp and encapsidated 
genome individually for assembly and packaging (Chapter 4).  Efficient cellular release 
of RVFV is dependent upon interactions between the encapsidated genome and the 
envelope glycoproteins (Chapter 4).  
We have developed and characterized a virus-like particle (VLP) system for RVFV 
(Chapter 2).  This RVF-VLP system allows us to investigate the protein-protein and 
protein-genome interactions necessary for generating infectious virus.  In our highly 
sensitive RVF-VLP system, we can substitute viral proteins from other viruses within the 
Phlebovirus genus to determine whether there is a block in virus replication/transcription, 
assembly, release, or entry processes.  Using representative viruses from several of the 
phlebovirus serocomplexes, we have identified barriers to reassortment between the 
RdRp and N, as well as the RdRp and Gn.  The interactions between the N and genome 
and N and Gn are conserved, but due to the RdRp limitations, viruses within the 
Phlebovirus genus have significant barriers to overcome in order to reassort.  Our results 
describe the molecular mechanisms underlying the barriers to phlebovirus reassortment.   
While we have identified protein-protein interactions with the RdRp as limiting 
phlebovirus reassortment, we have yet to clone functional heterologous RdRps to 
demonstrate the functionality of the heterologous N and Gn/Gc in replication, 
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transcription and the infection of target cells.  Therefore, we cannot make any firm 
conclusions until we provide the positive control for heterologous protein function. 
Results 
Representative N from the different serocomplexes of the Phlebovirus genus are highly 
conserved.  
 The N proteins from the RVFV (ZH501 strain, RVFV serocomplex), Toscana 
virus (TOSV) (Naples serocomplex, ELB strain), Punta Toro virus (PTV) (Punta Toro 
serocomplex, Adames strain), and Belterra virus (BEV) (Icoaraci serocomplex, 
BeAn356637 strain) exhibit high sequence identity at the amino acid level (Fig. 5.1). The 
high sequence identities suggest that all of the N proteins have similar structures and bind 
RNA similarly (Chapter 3).  Sequence alignments and pair-wise comparisons determined 
the amino acid identities of these selected viruses to vary between 49-57%, with the 
Toscana virus as the most divergent among these compared (Chapter 3).  
Heterologous N cannot function in place of RVFV N for transcription of the RVFV 
genome.  
BSR-T7 cells were transfected with minigenome, pN, pRdRp, and empty vector 
(pVAX1).  The RdRp requires N for replication and transcription of the genome (57); 
therefore, the raw luciferase units (RLU) generated when the minigenome and RdRp 
were expressed in the absence of N (Fig. 5.2) represents background levels. Increasing 
concentrations of N increases the expression of RdRp, as well as transcriptional activity 
(Fig. 5.2).  In contrast, increased expression of RdRp does not produce a corresponding 
increase in transcriptional activity (Fig. 5.2).  
To determine whether the heterologous N could function in place of RVFV N in 
transcription of the RVFV minigenome with the RVFV RdRp, BSR-T7 cells were 
transfected with minigenome, pRdRp, and pN, pTOSVN, pPTVN, or pBEVN, and 
analyzed by replicon assay and immunoblot (Fig. 5.3).  Expression of RVFV N resulted 
in luciferase activity of greater than 1000-fold background levels (-N) (Fig. 5.3).  In 
contrast, the expression of TOSV N, PTV N, or BEV N did not increase luciferase 
activity above background levels (Fig. 5.3).  These results demonstrate that none of the 
heterologous N can function in transcription of the RVFV minigenome, indicating the 
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heterologous N cannot functionally interact with either the RVFV RdRp and/or 
minigenome. 
Heterologous N do not exhibit dominant-negative inhibition.   
BSR-T7 cells were transfected with minigenome, pRdRp, and equivalent amounts 
of pN and empty vector (pVAX1), pN, pTOSVN, pPTVN, or pBEVN, then analyzed by 
replicon assay and immunoblot.  The luciferase expression was similar regardless of 
whether RVFV N was co-expressed with empty vector, TOSV N, PTV N, or BEV N 
(Fig. 5.3), indicating that the heterologous N do not function as dominant-negative 
inhibitors.  Additionally, the heterologous N cannot complement the RVFN for RLuc 
transcription, suggesting that the RVFN and heterologous N do not interact. 
The interactions between the N and RdRp are conserved between Phlebovirus 
serocomplexes.   
BSR-T7 cells were transfected with combinations of minigenome, pN or 
pTOSVN, and pRdRp, then cross-linked with DSP, lysed, immunoprecipitated and 
analyzed by SDS-PAGE electrophoresis and immunoblot (Fig. 5.4). The RVFV RdRp 
was immunoprecipitated only when co-expressed with RVFV N or TOSV N.  The 
expression of the RVFV minigenome was not required for RdRp immunoprecipitation, 
indicating that the heterologous N can interact with the RdRp independent of genome.  
We could not examine TOSV N expression levels due to weak detection levels of the 
antibody. 
Heterologous N cannot generate replication/transcription complexes.   
When expressed alone, the RVFV RdRp exhibits diffuse cytoplasmic staining 
(Chapter 4).  However, in the presence of N, the RVF RdRp forms large perinuclear 
puncta, which are believed to be the replication and/or transcription complexes (Fig. 
5.5A).  RdRp mutants incapable of producing puncta in the presence of N are also 
defective for transcribing the genome (Fig. 5.6 and 5.7). We investigated RdRp mutants 
in conserved residues throughout three of the conserved RdRp domains (Fig. 5.6 and 
5.7).  RdRp mutants Y928A, K1003A, and SS1093/4AA were found unable to form 
puncta, as well as transcriptionally defective (Fig. 5.6 and 5.7).  K1003A and 
SS1093/4AA may be misfolded due to their inability to form puncta, demonstrate 
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transcriptional activity, or interact with Gn, while RdRp mutant Y928A is likely properly 
folded due to its ability to be recruited by Gn. (Fig. 5.6, 5.7, and 5.8).  Therefore the 
inability of Y928A to form puncta may be due to an inability to form replication/ 
transcription complexes. 
To investigate whether the heterologous N form replication/transcription 
complexes, we transfected cells with pN, pTOSVN, pPTVN, or pBEVN alone or co-
expressed with pRdRp.  The heterologous N failed to change the localization of the RdRp 
to the large perinuclear puncta, suggesting that although the proteins may interact with 
the RdRp (Fig. 5.4), they may not form replication/ transcription complexes (Fig. 5.5B).  
The results were similar regardless of whether minigenome was co-expressed with RdRp 
and the heterologous N (Fig. 5.5B). 
Gn interactions necessary for N recruitment and particle release are conserved in the 
heterologous N.  
 BSR-T7 cells were transfected with minigenome, pRdRp, pGn, pGc, and pN, 
pTOSVN, pPTVN, or pBEVN.  The VLPs released into the media were harvested, 
clarified, and pelleted by high-speed ultracentrifugation.  The pelleted VLPs were 
analyzed by transmission electron microscopy (Fig. 5.5A) or by SDS-PAGE 
electrophoresis and immunoblot (Fig. 5.5B).  In previous studies, it has been suggested 
that RVF-VLPs cannot form without the N and envelope glycoproteins; therefore, VLPs 
expressing RVFV N or TOSV N were imaged using transmission electron microscopy.  
The VLPs were similar in size and morphology, incidating that TOSVN can function to 
form particles (Fig. 5.9A).  Previously, the genome and N have been found to be 
necessary for efficient cellular release of RVFV through interaction with the Gn envelope 
glycoprotein (Chapter 3).  The ability of the heterologous N to allow for efficient cellular 
release of VLPs was investigated.  Release efficiencies, as determined by release of the 
RVFV Gn/Gc, appeared similar for VLPs packaging RVFV N or the heterologous N 
(Fig. 5.9B), suggesting that the N interactions with the genome and Gn are conserved 
among the different phlebovirus serocomplexes.   
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Heterologous envelope glycoproteins cannot form infectious particles with RVFV RNP 
complexes.   
Since the Gn and encapsidated genome interaction is conserved for efficient 
release of virus, we hypothesized the TOSV Gn/Gc would be capable of packaging RVF 
ribonucleoprotein complexes (genome, N, and RdRp).  BSR-T7 cells were transfected 
with minigenome, pN or pTOSVN, pRdRp, pGn or pTOSV-Gn, and pGc or pTOSV-Gc.  
The VLPs were harvested and used to infect untransfected target cells.  Luciferase 
activity in transfected cells and VLP-infected target cells was analyzed.  Infectious VLPs 
were only produced by cells expressing all RVFV components (Fig. 5.10).  TOSV Gn 
and Gc were incapable of generating infectious VLPs containing RVFV minigenome, N, 
and RdRp, indicating the interactions with the RVF RNPs are not conserved between 
phlebovirus serocomplexes.  Since the encapsidated genome can interact with Gn, it is 
likely that the TOSV Gn cannot recruit the RVFV RdRp for virus assembly and 
packaging.  
Discussion 
The elucidation of the molecular barriers preventing phlebovirus reassortment is 
crucial to predicting the emergence of novel phleboviruses.  Gaining an understanding of 
the limitations to RVFV reassortment is particularly pertinent due to its severe 
pathogenesis and its capacity to spread to previously unaffected regions of the world.  
Although the phlebovirus genus is comprised of highly-related viruses, our results 
suggest that there are substantial barriers preventing their reassortment.   
The limitations governing phlebovirus reassortment appear to be dependent on the 
RdRp.  The heterologous N fail to allow transciption of the RVFV minigenome in the 
replicon assay, which contrasts previous studies showing that the RVFV RdRp and 
TOSV N can transcribe the RVFV minigenome (164).  Interestingly, Accardi et. al. did 
not detect any transcription by RVFV RdRp of the TOSV N-encapsidated minigenome, 
although they did detect transcription of the TOSV minigenome with the RVFV RdRp 
and RVFV N (164). Our replicon assay is very sensitive and quantitative, with levels 
reaching over 1000-fold background levels, so if there were signal generated, we should 
have been able to detect it.  However, we have not yet shown TOSV N to be functional 
for replication/transcription.  We are currently working to clone the TOSV RdRp to 
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verify all of the TOSV proteins are functional for replication/transcription and generation 
of infectious particles.   
We also demonstrated that the RdRp fails to functionally interact with the 
heterologous N to generate replication/transcription complexes and, likely, the TOSV Gn 
for assembly and packaging into virus particles.  To verify the RdRp cannot interact with 
the TOSV Gn, immunoprecipitation and immunofluorescence experiments determining 
the ability of TOSV Gn to interact with the RdRp for recruitment to the Golgi are 
currently being explored.   
Since the N and Gn are encoded by the S and M segments, respectively, the 
RdRp-encoding RVFV L segment must sort together with the RVFV S and M segments.  
Despite the stringency of the RVFV L segment, the RVFV S and M segments could sort 
with a more promiscuous L segment of a different virus. Once we understand the protein-
protein interactions between the RdRp and N and better define the interaction domain of 
the RdRp with Gn, we may be able to predict whether other viral RdRps could function 
with RVFV S and M segments.  Since there are separate blocks for RdRp interaction with 
N and Gn, it is less likely that a more promiscuous RdRp could circumvent both barriers.  
Therefore, if RVFV reassortants were generated, then we would anticipate that either the 
RVFV S or M segment would be switched rather than both segments.   
The restrictions for phlebovirus reassortment appear slightly different from those 
of other genera in the Bunyaviridae family.  The reassorted Ngari virus contained the S 
and L segments from BUNV and the M segment from BATV (11, 17), and experiments 
using cell culture systems with viruses within the Orthobunyavirus and Hantavirus 
genera of the Bunyaviridae family support a requirement for the S and L segments to sort 
together (5, 10-16, 18). In studies with viruses within the Hantavirus genus, cells were 
co-infected either with two different strains of the same virus or with two different 
viruses.  The progeny viruses were analyzed for generation of reassortants.  The 
investigators found strains of the same virus could reassort all of the segments, however, 
different viruses could only form viral reassortants that contained S and L segments from 
one virus and the M segment from the other virus (5).  It is likely that the S and L 
segments must sort together to prevent a barrier in replication and/or transcription of the 
genome.  These viruses may also have unique requirements for formation of 
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replication/transcription complexes.  However, these viruses do not require the M 
segment to sort together with the L (5, 11), indicating that the other genera do not exhibit 
the same block in RdRp packaging.  Therefore, the Phlebovirus genus differs in the 
limitations governing reassortment from the other genera of the Bunyaviridae family. 
Through investigating the ability of the highly conserved heterologous proteins to 
function in various steps in the replicative cycle, we can narrow the regions of interaction 
between the proteins.  While the N proteins from viruses within the Phlebovirus genus 
are ~50% identical at the amino acid level, the majority of the conserved residues map to 
the core of the structure (Chapter 3).  The surface-exposed regions available for protein-
protein interactions diverge significantly, which suggests why some of the protein-protein 
interactions with N may not be conserved between the phleboviruses.  Additionally, the 
RVFV N structure identified a RVFV N dimer as the basic unit of N multimerization, and 
the interactions necessary for dimer formation were discovered to be crucial for 
replication/transcription of the genome by the RdRp.  In support of our results showing 
no effect of the heterologous N on replication/transcription by RVFV N, the residues 
important for the N-N dimer interaction (RVFV N: Ala12, Trp 125) are not conserved 
between phleboviruses, suggesting that the heterologous N should not interact with 
RVFV N.  
Surprisingly, the heterologous N could interact with the RVFV RdRp, but could 
not form replication/transcription complexes.  The interaction with RVFV RdRp may be 
unstable or nonfunctional for the translocation of the RdRp to the replication/ 
transcription complexes.  Alternatively, RVFV N could change the localization of a host 
protein necessary for interaction with RdRp and its cytoplasmic aggregation.  The 
domain of N necessary for formation of these complexes appears not to be conserved 
within the Phlebovirus genus.  The generation of RVFV N constructs containing 
mutations within the divergent, surface-exposed regions could be examined for their 
ability to generate replication/transcription complexes.  These studies could identify the 
N-RdRp interaction domain necessary for complex formation and a target for RVFV 
antiviral development. 
The packaging of the encapsidated genome and efficient cellular release of RVFV 
requires interactions between the genome, N, and Gn. The heterologous Gn and N 
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proteins were able to efficiently generate particles, and therefore, the interactions 
between the genome, N, and Gn appear conserved.  The interaction domain of Gn with N 
has been previously identified as the first 30 amino acids of the cytoplasmic tail 
following the transmembrane domain (Chapter 4). Based on our results, the region of 
interaction should be conserved between the phlebovirus Gn. The Gn interaction domain 
contains several highly conserved bulky hydrophobic residues that we predict to be 
involved in N binding.  We solved the structure of RVFV N and modeled the structures 
of TOSV N, PTV N, BEV N, and Uukuniemi virus N (Chapter 3).  The structures share a 
conserved hydrophobic pocket predicted to be involved in protein-protein interactions.  
We propose that the highly conserved bulky hydrophobic amino acids within the Gn 
interaction domain insert into the conserved N hydrophobic pocket for the packaging of 
the encapsidated genome.  The only other evidence of phlebovirus assembly and budding 
is from the Uukuniemi virus, the most divergent of all phleboviruses.  Overby et. al. 
identified a region of Gn involved in N binding, which is non-existent in RVFV (86). 
Based on our data, the conserved Gn-N interaction domains could be targeted for the 
design of antivirals targeting the entire phlebovirus genus (except the divergent 
Uukuniemi virus), as well as any phlebovirus reassortant viruses generated in the future. 
Materials and Methods 
Cells 
BSR-T7 cells were a generous gift of Dr. K. Conzelmann (Max-von Pettenkofer-
Institut, Munchen, Germany).  Clonal BSR-T7 cell lines expressing the T7-RNA 
polymerase at high levels were obtained through limiting dilution.  The C3 clonal line 
was used for all experiments and was grown in Dulbecco’s Modified Eagle Medium 
(Invitrogen) supplemented with 10% fetal calf serum, and 1 mg/mL Geneticin. 
Viruses 
RVFV (ZH548 MP-12 vaccine strain), Toscana virus (ELB), Punta Toro virus 
(Adames strain), and Belterra virus (BeAn356637) were generous gifts of Dr. R. Tesh 
(World Reference Center of Emerging Viruses and Arboviruses).   
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Plasmid Constructs 
All plasmid constructs were generated by standard molecular cloning techniques 
and confirmed by sequencing.  The transcription and expression constructs for the RVFV 
plasmids, including pSTrRVFV-SNNSs::hRLuc, pRdRp, pN, pGc, and pGn, have 
been previously described (165).  The TOSVN was cloned from Toscana virus (ELB)-
infected cells through purifying the RNA using Trizol reagent, and using SuperScript3 
reverse transcriptase for generation of cDNA.  Similar methods were used to generate 
cDNA for PTVN (Adames), BEVN (BeAn356637), TOSV-Gc (ELB), and TOSV-Gn 
(ELB), except M-MLV reverse transcriptase generated the TOSV-Gn cDNA.  The 
TOSVN and PTVN genes were amplified using Phusion polymerase and primers 5’- 
GGATCCATGTCAGACGAGAATTATCG-3’/ 5’-
CTCGAGTCACTTGCCAACCTTGGCGC and 5’- 
GGATCCATGTCATACGAAGAGATTGC-3’/ 5’-
GTCGACCTAGAGGGATCTGAAGAC-3’, respectively, and ligated into pCR-Blunt.   
TOSVN was liberated by digesting with BamHI and XhoI, then, ligated into pVAX1.  
PTVN was digested with SalI and XhoI and ligated into pVAX1.  BEVN, TOSV-Gn and 






CTGCCTCGAGTTACTTGTTTTTCTTTTTTAGGGC-3’, respectively. The gene 
products were gel purified, digested with BamHI and XhoI, and ligated into pVAX1.  
Antibodies 
Polyclonal antibodies that were generated against RVFV, TOSV, BEV, and PTV 
in mice were generous gifts of Dr. P. Rollin (CDC).  Polyclonal antibodies recognizing 
RVFVN and RVFV RdRp were described previously (Chapters 2 and 4).  Hybridomas 
secreting neutralizing monoclonal antibodies recognizing RVFVN or RVF Gc were 
generous gifts of Dr. G. Ludwig (USAMRIID). 
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Replicon Assay 
BSR-T7 cells were plated at 1.2 x 10
6
 cells/10 cm plate.  The cells were 
transfected in the ratio 3.0ug pSTrRVFV-SNNSs::hRLuc, 6.0ug pN, and 9.0ug 
pRdRp/10 cm plate.  The amount of plasmid was scaled to the number of cells 
transfected.  The media was changed 24 h post-transfection, and the cells were harvested 
48 h post-transfection using Reporter Lysis Buffer (Promega) or Renilla Luciferase Lysis 
Buffer (Promega).  The cells were frozen at -80
o
C, then, thawed for the analysis of 
luciferase activity.  
VLP Assay 
BSR-T7 cells were plated at 1.2 x 10
6
 cells/10 cm plate.  The cells were 
transfected in the ratio 6.0ug pSTrRVFV-SNNSs::hRLuc, 6.0ug pN, 6.0ug pRdRp, 
3.0ug pGn, and 3.0ug pGc or the equivalent amount of heterologous expression 
plasmids/10 cm plate.  The amount of plasmid was scaled to the number of cells 
transfected.  The media was changed 24 h post-transfection and Benzonase (4ul/mL) was 
added. VLP-containing media was harvested at 48 h post-transfection and clarified by 
low-speed centrifugation for 10 minutes at 1200rpm.  The clarified media was treated 
with Benzonase (4ul/mL) for 2h at 37
o
C shaking, then, added to target cells.  After 24 h 
post-infection, the cells were harvested and analyzed for luciferase activity.  
Immunoblotting 
VLP-containing media from transfected cells was clarified by low-speed 
centrifugation, then, pelleted by high-speed ultra-centrifugation at 82,705 rcf for 4h at 
4oC.  The pelleted particles were analyzed by SDS-PAGE electrophoresis and 
immunoblot.   
Immunofluorescence confocal microscopy 
BSR-T7 cells were plated at 1.0 x 10
5
 cells/well of a 24-well plate.  The cells 
were transfected in the ratio of 0.25 ug minigenome, 0.5 ug pN, and 0.75 ug pRdRp, or a 
similar amounts of heterologous N constructs or empty vector were transfected.  After 
24h, the cells were fixed using 4% paraformaldehyde, perforated with 
PBS/BSA/1%Triton-X100, then stained with the appropriate antibodies.  The primary 
antibodies recognizing RVFVN, TOSVN, PTVN, and BEVN were monoclonal mouse 
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anti-RVFVN, polyclonal mouse anti-TOSV, polyclonal mouse anti-PTV, and polyclonal 
mouse anti-BEV, respectively.  RVFV RdRp was recognized with polyclonal rabbit anti-
RdRp.  Secondary antibodies goat anti-rabbit-488 and goat anti-mouse-Cy5 were used.  
The Olympus confocal microscope with Fluorview software at the University of 





Figure 5.1.  Phlebovirus genus N alignment.   
The N proteins from representative viruses from different serocomplexes of the Phlebovirus genus were 
cloned into mammalian expression vectors.  The invariant residues are listed in white with red background.  
Consensus residues are shown in red with white background and are boxed.  Variable residues are black 






Figure 5.2.  Increasing concentrations of N increase RdRp expression and transcriptional activity. 
BSR-T7 cells were transfected with RVFV minigenome, RVFV N, and RVFV RdRp, with increasing 
concentrations of RVFV N or RVFV RdRp.  After 24h post-transfection, the cells were harvested and 












Figure 5.3.  RVF replicon with heterologous N.   
BSR-T7 cells were transfected with RVFV minigenome, RVFV RdRp, and combinations of empty vector 
(pVAX), RVFV N, TOSV N, PTV N, and BEV N.  The raw luciferase units are shown with standard 














Figure 5.4.  Heterologous N interact with RdRp.   
BSR-T7 cells were transfected with combinations of RVFV minigenome, RVFV RdRp and RVFV N or 







Figure 5.5.  Heterologous N do not generate RdRp replication/transcription complexes.   
(A) BSR-T7 cells were transfected with RVFV RdRp and empty vector(EV) or RVFV RdRp was co-
expressed with RVFV N (RVFV N).  (B) Heterologous N proteins were co-expressed with empty vector 
(EV), the RVFV RdRp (RdRp, EV) or RVFV RdRp and RVFV minigenome (RdRp, genome).  RdRp 




Figure 5.6.  Expression and transcriptional activity of wild-type RdRp and RdRp mutants. 
Wildtype (WT) or mutant RdRp was co-expressed with RVFV N and RVFV minigenome.  Transcription of 
the RLuc reporter was determined by replicon assay with the values reported being relative to the Mock 
condition (lacking RdRp).  The cell lysates were analyzed for RdRp and N expression by immunoblot. 
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Figure 5.7.  RdRp mutant localization in presence of N.   
RdRp mutants (green channel) were analyzed by immunofluoresence microscopy when co-expressed with 
RVFV N and RVFV minigenome. 
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Figure 5.8.  Gn recruitment of RdRp mutants.   
Gn (red channel) was co-expressed with wildtype RdRp (WT) or mutants (green channel) and co-






Figure 5.9.  Heterologous N allow for efficient cellular release of VLPs.   
BSR-T7 cells were transfected with combinations of RVFV minigenome, RVFV RdRp, RVFV Gn/Gc and 
RVFV N, TOSV N, PTV N, or BEV N.  The VLPs were harvested and analyzed either by electron 























Figure 5.10.  Heterologous Gn/Gc cannot interact with RVF RNPs for generation of infectious particles.   
BSR-T7 cells were transfected with combinations of RVFV minigenome, RVFV N or empty vector, RVFV 
RdRp, and RVFV Gn/Gc, TOSV Gn/Gc, or empty vector for VLP assay.  Luciferase activities in 




Chapter 6  
 
Conclusion 
Negative-sense RNA viruses 
Negative-sense RNA viruses share common steps in their viral replicative cycles, 
including transcription and replication of the viral genome, assembly at cellular 
membranes, and release of virus from the cell for the infection of naïve cells.  Viruses 
have evolved intricate mechanisms to achieve these fundamental processes, utilizing both 
host and viral components.  Although the replicative cycles differ vastly in the possible 
methods of hijacking the host cell, all of the negative-sense RNA viruses express N, 
RdRp, and envelope glycoprotein(s).  While these proteins often perform multiple virus-
specific functions, they must also perform the general functions required for the 
propagation of all negative-sense RNA viruses. Through the study of these general steps 
in the viral replicative cycle of RVFV, mechanisms unique to RVFV have been 
identified, as well as features common to other viruses in the Bunyaviridae family.  We 
have discovered Gn to be sufficient for the independent recruitment and packaging of the 
encapsidated genome and the RdRp.  Through the interaction with Gn, the encapsidated 
genome functions as a trigger for virus release from the host cell, representing a novel 
and elegant mechanism for the cellular release of RNA viruses. 
Replication and transcription 
The interactions between the RdRp, N, and genome necessary for replication and 
transcription have been well-characterized for several negative-sense RNA viruses 
containing segmented or non-segmented genomes, but not for any of the viruses in the 
Bunyaviridae family. To gain greater insight into the replication and transcription 
mechanisms utilized by RVFV, the replication and transcription strategies of other 
negative-sense RNA viruses are compared and contrasted with RVFV.  
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Replication and transcription strategies for viruses of the order Mononegavirales 
The Mononegavirales (MNV) order is comprised of non-segmented negative-
sense RNA viruses, including the measles virus (Paramyxoviridae family), rabies virus 
(Rhabdoviridae family), Ebola virus (Filoviridae family), and borna disease virus 
(Bornaviridae family), which exhibit similar genome organization and replication and 
transcription strategies.  Replication and transcription are dependent upon the expression 
of the viral genome, N, RdRp, and an RdRp cofactor known as the phosphoprotein (P) 
(166).  P functions to stabilize the RdRp and is required for the interaction of the RdRp 
with N, bridging the two molecules and allowing RdRp access to the viral genome for 
transcription and replication (166). The increasing synthesis of P enhances these viral 
processes (166).  Viral transcription continues until the accumulation of free N surpasses 
a threshold, promoting a switch from transcription to replication (167).   
The crystal structures and electron microscopy images for N and P from several 
viruses within the MNV order suggest the utilization of similar replication and 
transcription strategies.  The N from respiratory syncytial virus (RSV) 
(Paramyxoviridae), rabies virus (Rhabdoviridae), and vesicular stomatitis virus 
(Rhabdoviridae) have been crystallized as multimeric ring-like structures bound to RNA 
(88-90). The borna disease virus (Bornaviridae) N has also been crystallized, in the 
absence of RNA (91).  All of the MNV N structures exhibit similar folds for the N- and 
C-terminal lobes, which are separated by a positively charged RNA-binding groove (89).  
The non-conserved regions among the MNV N form a variable region and the N- and C- 
terminal arms (89).  The N- and/or C- arms interact laterally for N-N contacts, adding 
stability to the RNP structures (89).  The C-arms are also suggested to interact with P for 
replication and transcription (168, 169).  
The RSV and vesicular stomatitis virus N structures have been modeled onto 3D 
reconstructed EM images of helical viral RNPs (89, 170).  The crystal structure of 
vesicular stomatitis virus was superimposed on that of RSV, and the N were found to 
bind RNA similarly, forming specific contacts with the RNA backbone, as well as non-
specific interactions with the RNA bases (89). The binding of P to N is proposed to 
generate a hinge movement of the N- and C-terminal lobes relative to each other.  The 
hinge movement would expose the buried RNA bases and RNA synthesis by the RdRp 
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(89). The N-RNA complex appears to be highly conserved within the MNV order (88-91, 
168, 170), and, based on the biological, biochemical, and structural studies, the viruses 
belonging to the MNV order likely replicate and transcribe the genome using similar 
strategies.   
The replication and transcription processes for the negative-sense non-segmented 
viruses differ significantly from the segmented viruses.  Nevertheless, RVFV shares 
some similarities with the non-segmented negative-sense RNA viruses.  While there is no 
P protein that is required for interaction between RVFV N and RdRp for replication and 
transcription, the RVFV N may functionally replace the MNV P in some respects.   For 
example, P stabilizes the expression of the RdRp for viruses within the MNV order, and 
our data suggest a similar phenomenon occurring with RVFV N (Chapter 5).  Upon 
expression of greater amounts of RVFV N, we detect greater levels of RdRp and 
increased transcriptional activity, suggesting that N is a limiting factor and can stabilize 
RdRp expression.  Additionally, RVFV N is similar in character to the MNV N. Upon 
expression of recombinant RVFV N in E. coli, a multimeric complex was formed tightly 
bound to the E. coli RNA.  The encapsidated RNA was resistant to extremes of salt and 
pH, as well as extensive treatment with RNase (Chapter 3).  Therefore, the RVFV N-
RNA complex was highly stable, and the RNA backbone was protected from RNase 
digestion.  The resistance to RNase digestion suggested that RVFV N binds to the RNA 
phosphate backbone, similar to MNV N.  Therefore, the negatively-charged RNA 
backbone would be predicted to bind a highly basic (positively charged) region on RVFV 
N.  However, upon crystallization of the RVFV N dimer, we detected no such groove. 
Although the RVFV N structure contained N- and C-terminal lobes, similar to MNV N, 
they were not separated by a positively charged RNA-binding groove (Chapter 3).  
Additionally, in contrast to MNV N, there were no N- or C-terminal arms extending from 
the core structure for lateral interactions with other N.  Instead, the N-terminus was 
involved in N-N interactions for formation of the dimer interface (Chapter 3).  Using a 
replicon assay, we found that mutation of a critical residue (Trp125) in the dimer 
interface resulted in loss of transcriptional activity of RdRp, suggesting that the dimer is a 
functional unit required for RVFV replication and transcription (Chapter 3).  However, a 
defect in dimerization could not be identified using protein cross-linking.  The mutation 
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likely destabilizes the dimer interface, allowing the dimers and multimers to form 
transiently.  To further demonstrate the defect, the N mutants should be investigated 
using size-exclusion chromatography and RNA binding studies.   
Since the RVFV N structure did not exhibit any obvious RNA binding groove, we 
sought to identify possible RNA-binding sites.  The phlebovirus genus contains N that are 
at least 41% identical at the amino acid level, with the exception of the Uukuniemi virus, 
which is much more divergent.  Therefore, the N should fold and bind to RNA similarly.  
As a result, the RNA-binding region should be conserved amongst phleboviruses, as well 
as be highly basic and surface exposed. Most of the phlebovirus N conservation mapped 
to the core of N, and the majority of surface-exposed residues were highly divergent or 
hydrophobic (Chapter 3).  A single potential RNA-binding site was identified (Chapter 
3).  To determine whether these residues are, indeed, involved in interaction with the 
genomic RNA, mutagenesis studies should be completed using the potential RNA 
binding region that we have identified.  Additionally, efforts should be continued for 
crystallizing N bound to RNA.   
Replication and transcription of segmented RNA viruses 
Most of the transcription and replication studies of the segmented negative-sense 
RNA viruses are performed with influenza A virus (FLUVA) from the Orthomyxoviridae 
family, and very little is known about these processes for the Bunyaviridae or 
Arenaviridae families.  Since the transcription and replication strategies for FLUVA have 
been well-studied, they may provide better insight into these processes for RVFV.  In 
contrast to RVFV, FLUVA contains eight genomic segments and requires N in addition 
to three polymerase subunit proteins (PA, PB1, and PB2) for replication and transcription 
of the genomic RNA (171).  Additionally, these processes for FLUVA occur in the 
nucleus instead of the cytoplasm.  For FLUVA transcription, PB2 binds to m7G methyl 
caps of host mRNAs, while PB1, possibly in concert with PA, cleaves the m7G methyl 
caps plus 10-15 nucleotides of RNA and uses them to prime transcription of the viral 
genes (171, 172).  Similar to FLUVA, RVFV utilizes the m7G methyl caps to prime 
transcription of the viral genes (40), however the caps are acquired in the cytoplasm for 
RVFV opposed to the nucleus for FLUVA (40, 171).  FLUVA PB1 appears to function 
as the transcriptase and replicase, as it contains the four conserved sequence motifs of 
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viral RdRps (171, 173).  Additionally, PB1 interacts with N and functions in RNA 
elongation (92).   
Structure of the N proteins 
Although RVFV performs replication and transcription within the cytoplasm and 
FLUVA carries out these processes in the nucleus, the strategies involved may be similar.  
The FLUVA N was crystallized in the absence of RNA, and a highly basic RNA-binding 
groove was suggested.   The RNA binding groove corresponded to the interface of the N- 
and C-terminal lobes (87), similar to the RNA-binding grooves identified for the viruses 
of the MNV order.  Recently, the predicted RNA-binding groove of FLUVA was verified 
through the generation of biologically active FLUVA RNP complexes, which were 
visualized using cryo-EM, and the bound RNA was resistant to RNase treatment (92).  
The crystal structures of FLUVA N and fragments of the RdRp were mapped onto the 
EM structures for the determination of the N-N interaction domains.  FLUVA N-N 
interaction was found to involve an extension of the N-terminus laterally to other N 
subunits (92), similar to the MNV N.   
Overall, the RVFV N structure is unique from FLUVA N and MNV N.  Through 
the crystallization of RVFV N we have identified a novel type of RNA binding protein.  
RVFV N represents a new classification of viral N, which binds RNA differently than the 
other viral N with known structures.  Despite the differences in N structure, the N 
crystallized from the Paramyxoviridae, Rhabdoviridae, Orthomyxoviridae, and 
Bunyaviridae families bind RNA non-specifically, are comprised of N- and C-terminal 
lobes, are predominantly -helical in composition, and protect the RNA backbone (88-
90, 92, 174, 175).  In contrast to all known N structures, RVFV N does not appear to bind 
RNA in a binding groove separating the N- and C-terminal lobes; therefore, it will be 
exciting to investigate how RVFV N interacts with the RNA genome.  Future work will 
focus on crystallizing the multimeric RVFV N bound to RNA, as well as examining 
RVFV N mutants in the predicted RNA binding region for changes in multimerization, 
RNA binding affinity, and transcription by the RdRp.  
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RdRp-N interactions 
While the RVFV and FLUVA N structures are unique, both N proteins interact 
with the RdRp.  The RVFV RdRp was found to interact with N in the absence of genome, 
and co-expression of N altered the localization of RdRp to perinuclear aggregates of 
unknown identity (Chapter 5).  Presumably, these RdRp aggregates are transcription 
and/or replication complexes, as we have identified RdRp mutants that no longer localize 
to these perinuclear punta in the presence of N and have reduced transcriptional activity 
(Chapter 5). One of the RdRp mutants was still capable of interacting with Gn; therefore, 
inability to form puncta was not due to misfolding of the RdRp (Chapter 5).   
The conservation of the RdRp and N interaction amongst viruses belonging to 
other serocomplexes of the Phlebovirus genus was also investigated.  While the 
heterologous N could interact with the RVFV RdRp as determined through 
immunoprecipitation studies in the presence of cross-linker, the N could not recruit the 
RdRp to the perinuclear structures (Chapter 5).  Additionally, the heterologous N could 
not support transcription by the RdRp in replicon assays, supporting the role of the 
perinuclear aggregates as replication/ transcription factories (Chapter 5).  Interestingly, 
the N from the Hantavirus genus (Bunyaviridae family) localize to cytoplasmic puncta, 
which have been previously identified as processing bodies (p-bodies) (176).  The 
function of p-bodies is to store and degrade cellular RNAs, resulting in degradation of 
m7G methyl caps (177, 178). Hantavirus N have been found to aid in the acquisition of 
m7G methyl caps from host mRNAs for priming of hantavirus transcription (179).  
RVFV N may also interact with the p-bodies and recruit the RdRp.  The localization of 
RdRp to p-bodies is an intriguing theory since the RdRp could acquire m7G methyl caps 
from host mRNA to initiate viral transcription.  
Future studies investigating the interactions between the RdRp and N necessary 
for the generation of the predicted replication/ transcription complexes should include the 
construction of N chimeras.  The crystal structure of N, as well as the homology models 
for the heterologous N would aid in the construction of the chimeric constructs.  The 
region required for generation of the replication/ transcription factories should not be 
conserved, since the heterologus N cannot recruit the RVFV RdRp to these structures.  
Therefore, the divergent surface exposed regions of N would be predicted to interact with 
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the RdRp.  A possible region of interest would be the C-terminus of N, which is a region 
of N that is more divergent (Chapter 3 and 5).  Moreover, the C-terminal salt bridge was 
identified as being critical for replication/ transcription by the RdRp (Chapter 3); this 
could be due to its inability to form replication/ transcription complexes.  In addition to 
investigating this mutant by immunofluorescence with co-expression of the RdRp, to 
narrow the region of interaction, chimeras expressing the N-terminus of RVFV N and the 
C-terminus of the heterologous N could be constructed.   A more detailed investigation of 
the N structure with regard to interaction with the RdRp may also yield other lucrative 
regions of N to investigate. 
Identification of the interaction domain between N and RdRp would aid in our 
understanding of how the RVFV replication/ transcription complexes are formed, but the 
discovery of the identity of the perinuclear structures would allow for increased 
investigation of the host interactions necessary for RVFV propagation and potential 
therapeutic targets.  The identity of the replication/ transcription complexes could be 
investigated using immunofluorescence microscopy.  The p-bodies could be stained 
along with the RdRp, and visualized by confocal microscopy in the presence and absence 
of N.  The localization of the RdRp to p-bodies would be anticipated only when co-
expressed with N.  Additionally, live cell imaging could be pursued with tagged RdRp 
constructs.  The RdRp still exhibits catalytic activity with a tag fused to the C-terminus 
(data not shown) (180).  Therefore, for identification of the replication/ transcription 
factories, live cell imaging studies could be performed with tagged RdRp co-expressed 
with tagged actin, tubulin, or p-body components.   
Shared mechanisms for replication and transcription 
Regardless of the differences between RVFV N and FLUVA N structures, 
parallels can be drawn between FLUVA and RVFV for replication and transcription.  A 
recent study has provided detailed insight into the processes of replication and 
transcription for FLUVA.  Jorba et. al. purified FLUVA RNP complexes containing 
transcription or replication deficient RdRp, then, investigated whether the defective 
RdRp-containing RNPs could be complemented in trans with wild-type RdRp (181).  
The transcription-deficient RNPs could not be complemented with wild-type RdRp, 
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leading the authors to conclude that FLUVA transcription of the RNA genome requires 
cis-acting RdRp (181).  In contrast, replication-deficient RNPs could be complemented in 
trans with wild-type RdRp, suggesting that genome replication in FLUVA is achieved by 
newly synthesized RdRp molecules in trans (181).  Jorba et. al. developed a model for 
FLUVA replication and transcription based on their results with the transcription and 
replication defective RdRps.  The initiation of genome replication was proposed to 
require an interaction between parental and newly synthesized RdRp that allows the 
newly synthesized RdRp access to the 3’ end of the genome (181).  The FLUVA RdRp 
oligomerizes in vivo, and it was suggested that replication of the genome may require 
oligomers of RdRp, perhaps forming a fixed scaffold for the generation of multiple newly 
synthesized RNPs (181).  A soluble RdRp distinct from the replicating RdRp is proposed 
to bind the newly synthesized RNP on the 5’ terminus and becomes the cis-acting RdRp 
on the new template (181).   
The processes of primary transcription and replication have been greatly 
elucidated for FLUVA using trans-complementation experiments.  Similar to the FLUVA 
we have investigated the ability of RdRp to complement replication and transcription in 
trans for RVFV (Chapter 4).  However, we did not have the capacity to differentiate 
between replication and transcription, nor did we use purified RNPs.  Infectious VLPs 
were used to deliver the RVF-RNPs to target cells, and RdRp and N were expressed in 
trans.  We found that expression of RdRp and N in trans could enhance replication and 
transcription by RNPs that were non-defective for replication and transcription (Chapter 
4).  However, if the particles were replication and transcription defective, then we could 
not complement in trans, similar to FLUVA.   Because we were using VLPs to deliver 
RNPs to the target cells, these results could be due to any of the following: the VLPs 
lacking competent RNPs are non-infectious, the VLPs are infectious, but the RNPs 
cannot access the RdRp/N expressed in trans due to subcellular localization, or, similar to 
FLUVA, the VLPs are infectious, but transcription of the viral genome cannot occur in 
trans.  Without a cis-acting transcriptionally active RdRp, the soluble RdRp may fail to 
gain access to the 3’ end.  Therefore, although the structure of RVFV N and FLUVA N 




Following transcription and replication, negative-sense RNA viruses assemble the 
viral components at cellular membranes prior to budding and release.  While negative-
sense RNA viruses generally require matrix or matrix-like proteins for the recruitment 
and packaging of the viral RNP complexes (182), the Bunyaviridae family of viruses 
does not encode these proteins.  Few studies with bunyaviruses have addressed the 
process of RNP recruitment and packaging.  However, with RVFV N and RVFV RdRp 
expressed in the cytoplasm and the envelope glycoproteins localizing to the Golgi 
apparatus (35), we hypothesized that the cytoplasmic portions of the envelope 
glycoproteins would recruit the RNP complexes for assembly at the Golgi.   
To investigate the processes of RVFV assembly and cellular release, we 
developed an RVF-VLP system.  Our RVF-VLP system generated particles antigenically 
indistinguishable from virulent RVFV.  The RVF-VLPs also responded to inhibitor 
compounds similar to RVFV (Chapter 2).  The minigenome design utilized the ambi-
sense nature of the S-segment, replacing the NSs gene with a GFP or RLuc reporter gene. 
Additionally, the minigenome had an internal deletion in the N gene, preventing its 
expression, thereby, allowing us to investigate the roles of N separately from the genome.   
The transcription of the minigenome reporter required the expression of RdRp and N and 
generated RLuc reporter signals over 1,500-fold background in transfected cells.  When 
the envelope glycoproteins were expressed as well, RVF-VLPs were produced, and RLuc 
reporter signals consistently exceeded 3,000-fold background levels in VLP-infected 
target cells (Chapter 2).   
Initially we utilized this highly-sensitive RVF-VLP system to investigate the 
recruitment of the RdRp and the encapsidated genome to the Golgi apparatus for 
packaging into virus particles.  We hypothesized that the cytoplasmic tail of Gn and/or 
Gc were necessary for the recruitment and packaging of the viral RNP complexes. 
Therefore, the packaging of the RdRp and encapsidated genome was investigated in the 
absence of Gn or Gc.  Particles were not efficiently produced lacking either glycoprotein; 
however, particles were detected in both conditions, and N was packaged in the absence 
of Gc (Chapter 4). To verify Gc was not required for the packaging of N, a truncated Gc 
mutant lacking the entire predicted cytoplasmic tail (GcW1) was expressed with Gn.  In 
125 
the absence of the Gc cytoplasmic tail, Gn packaged the RdRp and encapsidated genome, 
generating infectious RVF-VLPs (Chapter 4).  Therefore, Gn was sufficient for 
recruitment and packaging of the RdRp and encapsidated genome.  To investigate the 
regions of the Gn cytoplasmic tail required for these interactions, a Gn mutant lacking the 
C-terminal 40 amino acids of the 70 amino acid cytoplasmic tail was investigated 
(GnK48).  The GnK48 mutant RVF-VLPs packaged N, but not the RdRp, indicating that 
the Gn may utilize different regions of the cytoplasmic tail for interaction with the 
encapsidated genome and the RdRp (Chapter 4).  
The RVF-VLP results for packaging of RdRp were supported by studies using 
immunofluorescence microscopy.  Gn was shown to be necessary and sufficient for the 
recruitment of the RdRp to the Golgi apparatus.  Specifically, the terminal 40 amino acids 
of the Gn cytoplasmic tail were required for interaction between the RdRp and Gn 
(Chapter 4). The immunofluorescence microscopy also demonstrated that Gn could 
recruit the RdRp in the absence of encapsidated genome (Chapter 4).  These results, in 
combination with the GnK48 mutant RVF-VLPs packaging of N, but not the RdRp, 
suggest that the encapsidated genome is not recruited as an RNP complex with the RdRp 
bound.  Very few studies involving negative-sense RNA viruses have investigated the 
requirements for the packaging of the RdRp.  Usually, the packaging of N is interpreted 
as packaging of the entire RNP complex.  However, our data suggest that the 
encapsidated genome and the RdRp can be packaged separately, and assumptions should 
not be made regarding the packaging of all of the RNP components.  
Since the other families of negative-sense RNA viruses use matrix or matrix-like 
proteins for recruitment of the RNP complexes, parallels with RVFV assembly are 
difficult to establish outside of the Bunyaviridae family.  However, the mechanism 
utilized by RVFV may be similar to other bunyaviruses.  We investigated whether the Gn 
interactions with the encapsidated genome and the RdRp were conserved within the 
Phlebovirus genus (Chapter 5).  Using the VLP system, we discovered that heterologous 
N were packaged by RVFV Gn/Gc; therefore, the interaction between Gn and 
encapsidated genome was conserved among various serocomplexes of the Phlebovirus 
genus (Chapter 5).  In contrast, the interaction between the RdRp and Gn did not appear 
conserved.  Expression of the Gn and Gc from the Toscana virus (Phlebovirus genus) 
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with RVF-RNP complexes generated VLPs, but the particles did not generate reporter 
expression in target cells, suggesting the RdRp was not packaged (Chapter 5).  Therefore, 
we anticipate the interaction domain of Gn with N is conserved, and the interaction 
domain with the RdRp is not conserved amongst phleboviruses.  An amino acid sequence 
alignment of the Gn cytoplasmic tail from phleboviruses identified high sequence identity 
in the predicted N interaction domain, but low sequence identity for phleboviruses in the 
predicted RdRp interaction region (Fig.  6.1), supporting our results.  The N interaction 
domain contains several highly conserved bulky hydrophobic residues (Fig. 6.1), which 
would be likely candidates for interaction with the conserved hydrophobic pocket of N 
that we previously identified in the crystal structure of RVFV N (Chapter 3).   
The other viruses in the Bunyaviridae family that have been investigated for RNP 
assembly and packaging are the Tomato spotted wilt virus (TSWV) (Tospovirus genus) 
and the Uukuniemi virus (UUK) (Phlebovirus genus) (86, 127).  The interactions 
between the envelope glycoproteins and N from the TSWV were investigated previously 
using fluorescence resonance energy transfer (FRET) and fluorescence lifetime imaging 
microscopy (FLIM) techniques (127).  Interactions between both Gn and Gc with N were 
discovered, and the independent interactions with N stabilized the expression of both 
glycoproteins.  Competition experiments suggested that the interaction between N and Gn 
was much stronger than the interaction between N and Gc (127).  While interactions 
between RVFV Gc and N may function in the RVFV replicative cycle, RVFV Gc-N 
interactions are not required for the recruitment or packaging of the encapsidated 
genome.  Similar to RVFV, TSWV N interacted with the Gn cytoplasmic tail, and did not 
require the C-terminal region of the tail (20 amino acids) for interaction (127).  The Gn 
and N from TSWV diverge greatly from RVFV, so it is unlikely that the interaction 
domain between Gn and N would be conserved; however, the same region of the Gn 
cytoplasmic tail appears to be important.  
The only other study characterizing the assembly and packaging of viruses in the 
Bunyaviridae family was performed with the Uukuneimi virus (UUK) (Phlebovirus 
genus).  A UUK-VLP system was utilized to investigate packaging of RNPs (86). 
Mutants were generated for the entire UUK Gn cytoplasmic tail, and the residues 
important for RNP recruitment were determined by the absence of packaged N and lack 
127 
of infectious particles.  The investigators discovered that the Gn cytoplasmic tail was 
required for packaging of UUK N, similar to TSWV and our observations with RVFV 
(86).  However, the region identified corresponded to the last two amino acids of the Gn 
cytoplasmic tail (86).  In contrast, the RVFV N interaction domain did not require the last 
40 amino acids of the C-terminal region of the tail (Chapter 4).  These results suggest that 
UUK utilizes a different region of interaction for packaging N than RVFV and the other 
serocomplexes of the Phlebovirus genus.   The use of a unique method for RNP 
packaging by UUK would not be surprising as UUK exhibits low sequence identity to the 
other phlebovirus serocomplexes.  Therefore, the Gn-N interaction domain appears 
conserved for phleboviruses, with the exception of the UUK virus. 
We are currently pursuing the design of peptides corresponding to the region of 
Gn predicted to interact with N.  The peptides will be investigated for binding to N in the 
presence and absence of genome.  We predict that the hydrophobic pocket will be the site 
of Gn interaction for N, as it is hydrophobic and conserved amongst phleboviruses.  If 
peptides bind N, then crystallization of the N bound to the Gn peptide could be initiated.  
The peptides, themselves, may function as inhibitors to RVFV propagation and should be 
investigated for antiviral effects in an RVFV infection.  Additionally, the crystallization 
of Gn peptides to N could allow for the design of small molecule inhibitors.  The Gn-N 
interaction could represent a possible therapeutic target for viruses of the Phlebovirus 
genus, including any emergent reassorted viruses. 
In contrast to the Gn-N interaction domain, the Gn region of interaction with the 
RdRp is not highly conserved for phleboviruses (Fig. 6.1).  The RVFV Gn-RdRp 
interaction may be further refined through the generation of Gn cytoplasmic tail 
chimeras.  The TOSV Gn appears to package the RVFV encapsidated genome, but not 
the RVFV RdRp (Chapter 5).  Based on our results demonstrating the RVFV Gn tail 
residues 31-70 (Fig. 6.1) contain a region required for recruitment and packaging of the 
RVFV RdRp (Chapter 4), a chimera containing TOSV Gn residues 1-25 and RVFV Gn 
residues 26-70 (Fig. 6.1) should be capable of RdRp recruitment.  Therefore, the 
expression of chimeric Gn with TOSV Gc, and RVFV RNP complexes should generate 
infectious VLPs.  The region of Gn-RdRp interaction could be narrowed further through 
generation of a chimera containing TOSV Gn residues 1-47 and RVFV Gn residues 48-
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70 (Fig. 6.1).  Successful Gn-RdRp interaction could be determined by generation of 
reporter signal in VLP-infected cells. 
Based on our studies of RVFV assembly, the encapsidated genome and RdRp can 
be independently recruited by Gn.  However, we did not decipher whether the genome 
and N could interact with Gn independently.  The interaction of Gn with N in the 
presence and absence of genome can be investigated using immunoprecipitation 
experiments.  Whether there is an interaction between Gn and the genome could also be 
investigated using filter binding assays.  If Gn binds the genome, then affinities could be 
calculated for the binding of Gn to specific RNAs.  Through this method, it is possible 
that the RVFV genome packaging signal could be identified. 
Cellular release of virus 
The budding and release of virus from the host cell is the final stage of the viral 
replicative cycle.  Using the RVF-VLP system, we investigated the RVFV components 
necessary for efficient cellular release of particles.  We transfected cells with all the viral 
structural components or mixtures lacking one or more of the components, then harvested 
the particles to determine whether the RVF-VLPs were efficiently released from the cell.  
The RVF-VLPs were analyzed by EM or by immunoblot, and the efficiency of RVF-VLP 
cellular release was calculated. Using our RVF-VLP system, we discovered that the 
encapsidated genome was necessary for efficient RVF-VLP release, demonstrating a 
novel mechanism for virus release utilizing the viral genome as a trigger.   
RVF-VLPs were efficiently produced only when the encapsidated genome was 
expressed in combination with the envelope glycoproteins.  While no particles could be 
visualized for conditions lacking N or the envelope glycoproteins, particles were 
visualized by EM for conditions lacking genome; however, they were not efficiently 
released.  When the RdRp was not expressed, RVF-VLPs were generated at levels similar 
to wild-type RVF-VLPs, indicating that the RdRp was not required for the cellular 
release of virus.  Therefore, only the encapsidated genome and glycoproteins were 
required. The requirement for encapsidated genome for efficient release of RVFV 
illustrates an elegant mechanism.  Through requiring genome for efficient release of 
particles, most RVFV particles should contain genome and be infectious.  The efficient 
release of infectious particles by bunyaviruses is supported by experiments performed 
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using the Bunyamwera virus (Orthobunyavirus genus).  Lowen et. al. (2005) determined 
the particle:plaque-forming unit ratio for the Bunyamwera virus to approach one, 
suggesting most of the particles generated were infectious, hence, contained genome 
(183).  
Generally, negative-sense RNA viruses not only require matrix proteins for the 
assembly of virus particles at cellular membranes, but also for the budding of virus from 
the cell (139-147, 149-152, 184).  Although the matrix protein might not be the only viral 
protein required for efficient release, it is usually necessary.  After linking the viral RNPs 
with the envelope glycoprotein(s), the matrix protein can trigger particle budding and 
cellular release.  To compensate for the lack of a matrix protein, bunyaviruses have 
developed an elegant mechanism for virus release.  The Gn can independently recruit the 
encapsidated genome, RdRp, and Gc for formation of particles, and the cellular release of 
virus is dependent upon the interaction between the encapsidated genome and Gn.  We 
propose the interaction between the encapsidated genome and Gn triggers virus release 
through stimulating the budding of virus particles into the lumen of the Golgi apparatus.  
The low particle-to-pfu ratio for the Bunyamwera virus demonstrates that all three 
genomic segments are packaged. Previous studies have suggested the RVFV L, M, and S 
segments to be packaged at the molar ratio of 1:4:4, respectively (41); therefore, we 
propose that a critical amount of genome must interact with Gn before sufficient 
curvature in the membrane is generated to allow budding. The critical amount of genome 
would encourage the packaging of all three segments similar to the molar ratio of 
1L:4M:4S (~28 kb).  The virus would bud upon Gn binding this critical quantity of 
encapsidated genome.  
While we have identified the encapsidated genome as required for efficient 
cellular release of RVFV, similar studies with the UUK virus have demonstrated the use 
of different mechanisms for virus release.  Using a VLP system developed for the UUK 
virus, Overby et. al. found the envelope glycoproteins to be released at high levels 
regardless of the presence of RNPs (185).  The UUK Gn/Gc could bud into the lumen of 
the Golgi apparatus and release from the cell without the expression of any other viral 
component (185).  The UUK Gn/Gc are very divergent in amino acid sequence from 
RVF Gn/Gc, and it is not surprising that there may be differences in the virus release 
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mechanisms.  However, it has not been investigated whether the expression of the 
encapsidated genome may increase the efficiency of release for UUK.  
In contrast to the UUK serocomplex, the viruses belonging to other phlebovirus 
serocomplexes contain a conserved region for Gn-N interaction, and the N from 
representative viruses of several serocomplexes functioned in the efficient cellular release 
of RVFV Gn/Gc.  Since the encapsidated genome is required for efficient release, then 
the heterologous N must also functionally interact with the RVFV minigenome.   
Therefore, the regions of Gn and N necessary for efficient release of virus appear 
conserved amongst the phleboviruses, with the exception of the UUK virus. 
Screening of small molecule inhibitors 
The development of the RVF-VLP system was paramount in investigating the 
steps in the RVFV replicative cycle, but it also could be an invaluable tool for screening 
RVFV small molecule inhibitors.  Using the RVF-VLP system, we could identify potent 
inhibitors of RVFV using a luciferase read-out that is scaleable for high-throughput 
screening.  Our VLP system is extremely sensitive, and routinely generates luciferase 
expression of over 3000-fold background levels in VLP-infected cells. This extreme 
sensitivity allows for the differentiation between strong RVFV inhibitors from weak or 
moderate inhibitors targeting viral replication, transcription or cell entry. After inhibitors 
have been identified, all of the tools that we have developed for investigation of the 
RVFV replicative cycle could be utilized as secondary screening tools for determining 
the step in the replicative cycle that the inhibitor is acting upon.  For example, we can 
perform RVF-VLP infection time-courses adding inhibitor at different times post-
infection, replicon assays to determine whether inhibitors act on replication and/or 
transcription, as well as immunoprecipitations and immunofluorscence microscopy to 
determine whether inhibitors block the RdRp-N interaction or formation of replication 
and transcription complexes. Finally, we can investigate whether the inhibitors can 
reduce authentic RVFV titer using plaque assays. 
Summary 
The elucidation of the steps in the RVFV replicative cycle will aid in our 
understanding of RVFV and the identification of possible therapeutic targets.  Using our 
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results in combination with studies from other negative-sense RNA viruses, we propose a 
model for the RVFV replicative cycle.  
Upon entry of RVFV into host cells, the RNP complexes are released into the 
cytoplasm.  Transcription of the viral genome is primed by m7G methyl caps cleaved 
from host mRNAs, and the cis-acting RdRp transcribes the genome, generating viral 
mRNAs to be translated by the host machinery.  The newly synthesized RdRps interact 
with the cis-acting RdRps, and then replicate the genome.  Newly synthesized N 
encapsidates the genomic RNA, and the encapsidated genome and RdRp are recruited to 
the Golgi apparatus through independent interactions with the Gn cytoplasmic tail.  
Multiple interactions between Gn proteins and the encapsidated genomic segments 
trigger budding of particles into the Golgi apparatus after sufficient quantity of 
encapsidated genomic segments bind to Gn proteins.  The Golgi apparatus fragments, and 

















Figure 6.1.  Alignment of the Phlebovirus Gn cytoplasmic tail. 
The predicted N and RdRp interaction domains of the Gn cytoplasmic tail are defined. Invariant residues 
are show in white with red background, consensus residues are shown in red with white background, and 
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